<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Digital Diagnostics</journal-id><journal-title-group><journal-title xml:lang="en">Digital Diagnostics</journal-title><trans-title-group xml:lang="ru"><trans-title>Digital Diagnostics</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Digital Diagnostics</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2712-8490</issn><issn publication-format="electronic">2712-8962</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">532728</article-id><article-id pub-id-type="doi">10.17816/DD532728</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Научные обзоры</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="zh"><subject>科学评论</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Preparation for radioiodine therapy in patients with differentiated thyroid cancer: a modern perspective (a review)</article-title><trans-title-group xml:lang="ru"><trans-title>Современный взгляд на основные аспекты подготовки пациентов с дифференцированным раком щитовидной железы к радиойодтерапии: научный обзор</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>目前对分化型甲状腺癌患者放射性碘治疗准备工作主要方面的看法：文献综述</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-1632-2197</contrib-id><contrib-id contrib-id-type="researcherid">IUO-4237-2023</contrib-id><name-alternatives><name xml:lang="en"><surname>Reinberg</surname><given-names>Maria V.</given-names></name><name xml:lang="ru"><surname>Рейнберг</surname><given-names>Мария Валентиновна</given-names></name><name xml:lang="zh"><surname>Reinberg</surname><given-names>Maria V.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>mrezerford12@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3220-2438</contrib-id><contrib-id contrib-id-type="spin">3079-8033</contrib-id><name-alternatives><name xml:lang="en"><surname>Slashchuk</surname><given-names>Konstantin Y.</given-names></name><name xml:lang="ru"><surname>Слащук</surname><given-names>Константин Юрьевич</given-names></name><name xml:lang="zh"><surname>Slashchuk</surname><given-names>Konstantin Y.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><bio xml:lang="zh"><p>MD, Cand. Sci. (Med.)</p></bio><email>slashuk911@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5592-4727</contrib-id><contrib-id contrib-id-type="spin">4398-9536</contrib-id><name-alternatives><name xml:lang="en"><surname>Trukhin</surname><given-names>Alexey A.</given-names></name><name xml:lang="ru"><surname>Трухин</surname><given-names>Алексей Андреевич</given-names></name><name xml:lang="zh"><surname>Trukhin</surname><given-names>Alexey A.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Engin.)</p></bio><bio xml:lang="ru"><p>канд. техн. наук</p></bio><bio xml:lang="zh"><p>Cand. Sci. (Engin.)</p></bio><email>Alexey.trukhin12@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-4970-8911</contrib-id><contrib-id contrib-id-type="spin">4330-0263</contrib-id><name-alternatives><name xml:lang="en"><surname>Avramova</surname><given-names>Karina I.</given-names></name><name xml:lang="ru"><surname>Аврамова</surname><given-names>Карина Игоревна</given-names></name><name xml:lang="zh"><surname>Avramova</surname><given-names>Karina I.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>dravramovak@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3785-0335</contrib-id><contrib-id contrib-id-type="spin">7845-2194</contrib-id><name-alternatives><name xml:lang="en"><surname>Sheremeta</surname><given-names>Marina S.</given-names></name><name xml:lang="ru"><surname>Шеремета</surname><given-names>Марина Сергеевна</given-names></name><name xml:lang="zh"><surname>Sheremeta</surname><given-names>Marina S.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><bio xml:lang="zh"><p>MD, Cand. Sci. (Med.)</p></bio><email>marina888@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Endocrinology Research Centre</institution></aff><aff><institution xml:lang="kk"></institution></aff><aff><institution xml:lang="pt"></institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр эндокринологии</institution></aff><aff><institution xml:lang="zh">Endocrinology Research Centre</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Endocrinology Research Centre</institution></aff><aff><institution xml:lang="ru">Национальный медицинский исследовательский центр эндокринологии</institution></aff><aff><institution xml:lang="zh">Endocrinology Research Centre</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2023-10-10" publication-format="electronic"><day>10</day><month>10</month><year>2023</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-12-15" publication-format="electronic"><day>15</day><month>12</month><year>2023</year></pub-date><volume>4</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><issue-title xml:lang="zh"/><fpage>543</fpage><lpage>568</lpage><history><date date-type="received" iso-8601-date="2023-07-08"><day>08</day><month>07</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-09-05"><day>05</day><month>09</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, Эко-вектор</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; 2023, Eco-Vector</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-вектор</copyright-holder><copyright-holder xml:lang="zh">Eco-Vector</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://jdigitaldiagnostics.com/DD/article/view/532728">https://jdigitaldiagnostics.com/DD/article/view/532728</self-uri><abstract xml:lang="en"><p>Thyroid cancer is the most prevalent tumor of the endocrine system, accounting for 1%–3% of all malignant neoplasms as of 2021. Differentiated forms, papillary and follicular, with a relatively favorable prognosis, are detected in 90% of cases. The combination of surgical treatment, subsequent suppressive hormonal therapy, and radioiodine therapy provides a favorable prognosis in patients with differentiated thyroid cancer. However, an insufficient response to radioiodine therapy may be possible, which may be associated with multiple factors, including the preparation step for radioiodine therapy. To date, the question of choosing the optimal method of patient preparation remains relevant. This paper presents a review of the scientific literature on the preparation of patients with differentiated thyroid cancer for radioiodine therapy. The principles of preparation are based on the recommendations of leading expert societies, and publications related to this topic are highlighted and summarized, including the adverse events associated with radioiodine therapy, quality of life, efficacy, and long-term results of treatment. The main purpose of this review was to provide a comprehensive insight into the methods of preparing a patient with differentiated thyroid cancer for radioiodine therapy, highlight existing problems and promising areas of research, and modernize treatment toward personalized therapy. Scientific articles and reviews from the National Library of Medicine, Cochrane Library, and Google Scholar databases, published up to the end of January 2023, were searched by the keywords listed below in their various combinations. Recommendations from the following scientific communities were used: Russian Clinical Guidelines for Differentiated Thyroid Cancer, American Thyroid Association, European Thyroid Association, National Comprehensive Cancer Network, European Association of Nuclear Medicine, British Thyroid Association, and European Society for Medical Oncology. Articles not available in full, not in English or Russian, or systematic reviews of a similar topic, were excluded. In total, 124 sources were selected and analyzed, general tendencies of modern approaches to preparation for radioiodine therapy and actual problems were highlighted, concepts of optimization of preparation for radioiodine therapy within the framework of personalized therapy were covered, and results and conclusions were presented.</p></abstract><trans-abstract xml:lang="ru"><p>Рак щитовидной железы — наиболее распространённая опухоль эндокринной системы, составляющая 1–3% всех злокачественных новообразований (по состоянию на 2021 год). В 90% случаев выявляют дифференцированные формы — папиллярный и фолликулярный варианты — обладающие относительно благоприятным прогнозом.</p> <p>Комбинация хирургического лечения и последующей супрессивной гормональной терапии, радиойодтерапии, обеспечивают благоприятный прогноз у пациентов с высокодифференцированным раком щитовидной железы. Тем не менее сохраняется вероятность недостаточного ответа на радиойодтерапию, что может быть ассоциировано со многими факторами, включая этап подготовки к её проведению. На сегодняшний день сохраняется актуальным вопрос о выборе оптимального метода подготовки пациента к терапии радиоактивным йодом.</p> <p>В публикации представлен обзор научной литературы, посвящённой аспектам подготовки пациента с высокодифференцированным раком щитовидной железы к проведению терапии радиоактивным йодом. Освещены и обобщены принципы подготовки пациентов на основании рекомендаций ведущих экспертных сообществ и публикаций по данной теме, приняты во внимание нежелательные явления, ассоциированные с радиойодтерапией, качество жизни пациентов, эффективность и отдалённые результаты лечения.</p> <p>Основная цель обзора — составить целостное представление о методах подготовки пациента с высокодифференцированным раком щитовидной железы к проведению радиойодтерапии, осветить существующие проблемы и перспективные направления исследований с целью модернизации лечения в сторону персонализированной терапии.</p> <p>Был проведен поиск научных статей и обзоров, опубликованных до конца января 2023 года, в базах данных National Library of Medicine, The Cochrane Library и Google Scholar по следующим ключевым словам: подготовка к радиойодтерапии, тиреотропин альфа, отмена тиреоидных гормонов, побочные эффекты, йод-ограниченная диета, сиалоаденит, первичный гипотиреоз, качество жизни, тиреоидэктомия, дифференцированный рак щитовидной железы, эффективность радиойодтерапии — в их различных комбинациях. Использовались рекомендации по высокодифференцированному раку щитовидной железы следующих научных сообществ: Российские клинические рекомендации по высокодифференцированному раку щитовидной железы, American Thyroid Association, European Thyroid Association, The National Comprehensive Cancer Network, European Association of Nuclear Medicine, British Thyroid Association, European Society for Medical Oncology. Критериями исключения были статьи, не доступные в полном объёме, не на английском или русском языках, систематические обзоры на аналогичную тему. Всего было отобрано и проанализировано 124 источника, выделены общие тенденции современного подхода к подготовке пациентов к терапии радиоактивным йодом и актуальные проблемы, освещены концепции оптимизации подготовки к радиойодтерапии в рамках персонализации терапии, сформированы результаты и выводы.</p></trans-abstract><trans-abstract xml:lang="zh"><p>甲状腺癌是内分泌系统中最常见的肿瘤。它占所有恶性肿瘤的1%-3%（截至2021年）。在90%的病例中，可发现分化型甲状腺癌（乳头状癌和滤泡状癌）。它们的预后相对较好。</p> <p>对于高分化甲状腺癌患者来说，手术治疗和随后的激素抑制治疗、放射性碘治疗相结合的预后良好。不过，放射性碘治疗仍有可能出现反应不充分的情况。这可能与许多因素有关，包括准备阶段。迄今为止，如何选择最佳的放射性碘治疗准备方法仍是一个重要问题。</p> <p>该出版物对有关高分化甲状腺癌患者接受放射性碘治疗的准备问题的科学文献进行了综述。根据主要专家团体的建议和有关该主题的出版物，我们对患者准备工作的原则进行了介绍和总结。文章还考虑了（1）与放射性碘治疗相关的不良反应；（2）患者的生活质量；（3）疗效；（4）治疗的长期结果。</p> <p>这篇综述的主要目的是提供一个全面的视角，介绍为高分化甲状腺癌患者接受放射性碘治疗做准备的方法，强调现有的问题和有前途的研究方向，以便使治疗现代化，实现个性化治疗。</p> <p>在National Library of Medicine、The Cochrane Library和Google Scholar数据库中检索了截至2023年1月底发表的科学文章和综述。检索时使用了以下关键词：为放射性碘治疗做准备、促甲状腺素α、停用甲状腺激素、副作用、禁碘饮食、涎腺炎、原发性甲状腺功能减退症、生活质量、甲状腺切除术、分化型甲状腺癌、放射性碘治疗的疗效。采用了以下科学界关于高分化甲状腺癌的建议：俄罗斯高分化甲状腺癌临床指南、美国甲状腺协会、欧洲甲状腺协会、American Thyroid Association、European Thyroid Association、The National Comprehensive Cancer Network、European Association of Nuclear Medicine、British Thyroid Association、European Society for Medical Oncology。排除标准为：未提供全文的文章；非英语或俄语文章；类似主题的系统综述。共选择并分析了124个资料来源。本文强调现代放射性碘治疗患者准备工作的总体趋势和当前存在的问题，指出在治疗个性化框架内优化放射性碘治疗准备的概念，最后得出结论。</p></trans-abstract><kwd-group xml:lang="en"><kwd>differentiated thyroid cancer</kwd><kwd>radioiodine therapy</kwd><kwd>low-iodine diet</kwd><kwd>thyrotropin alpha</kwd><kwd>methods of preparation</kwd><kwd>side effects</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>дифференцированный рак щитовидной железы</kwd><kwd>терапия радиоактивным йодом</kwd><kwd>йод-ограниченная диета</kwd><kwd>тиреотропин альфа</kwd><kwd>методы подготовки</kwd><kwd>нежелательные явления</kwd></kwd-group><kwd-group xml:lang="zh"><kwd>分化型甲状腺癌</kwd><kwd>放射性碘治疗</kwd><kwd>禁碘饮食</kwd><kwd>促甲状腺素α</kwd><kwd>准备方法</kwd><kwd>不良反应</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">Правительство Российской Федерации</institution></institution-wrap><institution-wrap><institution xml:lang="en">Government of the Russian Federation</institution></institution-wrap><institution-wrap><institution xml:lang="zh">Government of the Russian Federation</institution></institution-wrap></funding-source><award-id>123021000041-6</award-id></award-group></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Vanushko VE, Tsurkan AYu. Treatment of differentiated thyroid cancer: cureunt statement of the problem. Clinical and experimental thyroidology. 2010;6(2):24–33. (In Russ). doi: 10.14341/ket20106224-33</mixed-citation><mixed-citation xml:lang="ru">Ванушко В.Э., Цуркан А.Ю. Лечение дифференцированного рака щитовидной железы: состояние проблемы // Клиническая экспериментальная тиреоидология. 2010. Т. 6, № 2. С. 24–33. doi: 10.14341/ket20106224-33</mixed-citation><mixed-citation xml:lang="zh">Vanushko VE, Tsurkan AYu. Treatment of differentiated thyroid cancer: cureunt statement of the problem. Clinical and experimental thyroidology. 2010;6(2):24–33. (In Russ). doi: 10.14341/ket20106224-33</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Kaprin AD, Starinskii VV, Shakhzadova AO, editors. Zlokachestvennye novoobrazovaniya v Rossii v 2021 godu (zabolevaemost’ i smertnost’). Moscow: MNIOI im. P.A. Gertsena −of NMRRC of the Ministry of Health of Russia; 2022. (In Russ).</mixed-citation><mixed-citation xml:lang="ru">Злокачественные новообразования в России в 2021 году (заболеваемость и смертность) / под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. Москва : МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022.</mixed-citation><mixed-citation xml:lang="zh">Kaprin AD, Starinskii VV, Shakhzadova AO, editors. Zlokachestvennye novoobrazovaniya v Rossii v 2021 godu (zabolevaemost’ i smertnost’). Moscow: MNIOI im. P.A. Gertsena −of NMRRC of the Ministry of Health of Russia; 2022. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. The Journal of Clinical Endocrinology &amp; Metabolism. 2006;91(8):2892–2899. doi: 10.1210/jc.2005-2838</mixed-citation><mixed-citation xml:lang="ru">Durante C., Haddy N., Baudin E., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy // The Journal of Clinical Endocrinology &amp; Metabolism. 2006. Vol. 91, N 8. P. 2892–2899. doi: 10.1210/jc.2005-2838</mixed-citation><mixed-citation xml:lang="zh">Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. The Journal of Clinical Endocrinology &amp; Metabolism. 2006;91(8):2892–2899. doi: 10.1210/jc.2005-2838</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Cancer Stat Facts: Thyroid Cancer [Internet]. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. [cited 2023 Sep 1]. Available from: https://seer.cancer.gov/statfacts/html/thyro.html</mixed-citation><mixed-citation xml:lang="ru">Cancer Stat Facts: Thyroid Cancer [Internet]. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. [дата обращения: 01.09.2023]. Доступ по ссылке: https://seer.cancer.gov/statfacts/html/thyro.html</mixed-citation><mixed-citation xml:lang="zh">Cancer Stat Facts: Thyroid Cancer [Internet]. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. [cited 2023 Sep 1]. Available from: https://seer.cancer.gov/statfacts/html/thyro.html</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Braverman LE, Cooper DS, Kopp P. Werner &amp; Ingbar’s The Thyroid: A Fundamental and Clinical Text. 11th ed.. Philadelphia, PA: Wolters Kluwer; 2021.</mixed-citation><mixed-citation xml:lang="ru">Braverman L.E., Cooper D.S., Kopp P. Werner &amp; Ingbar’s The Thyroid: A Fundamental and Clinical Text. 11th ed. // Philadelphia, PA : Wolters Kluwer, 2021.</mixed-citation><mixed-citation xml:lang="zh">Braverman LE, Cooper DS, Kopp P. Werner &amp; Ingbar’s The Thyroid: A Fundamental and Clinical Text. 11th ed.. Philadelphia, PA: Wolters Kluwer; 2021.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Hassan A, Razi M, Riaz S, et al. Survival Analysis of Papillary Thyroid Carcinoma in Relation to Stage and Recurrence Risk: A 20-Year Experience in Pakistan. Clinical Nuclear Medicine. 2016;41(8):606–613. doi: 10.1097/RLU.0000000000001237</mixed-citation><mixed-citation xml:lang="ru">Hassan A., Razi M., Riaz S., et al. Survival Analysis of Papillary Thyroid Carcinoma in Relation to Stage and Recurrence Risk: A 20-Year Experience in Pakistan // Clinical Nuclear Medicine. 2016. Vol. 41, N 8. P. 606–613. doi: 10.1097/RLU.0000000000001237</mixed-citation><mixed-citation xml:lang="zh">Hassan A, Razi M, Riaz S, et al. Survival Analysis of Papillary Thyroid Carcinoma in Relation to Stage and Recurrence Risk: A 20-Year Experience in Pakistan. Clinical Nuclear Medicine. 2016;41(8):606–613. doi: 10.1097/RLU.0000000000001237</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Well-differentiated thyroid cancer. Clinical guidelines. ID 329. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. 2020. Available from: https://cr.minzdrav.gov.ru/recomend/329_1 (In Russ)</mixed-citation><mixed-citation xml:lang="ru">Клинические рекомендации — Дифференцированный рак щитовидной железы. ID 329. Одобрено Научно-практическим Советом Минздрава РФ. 2020. Режим доступа: https://cr.minzdrav.gov.ru/recomend/329_1 Дата обращения: 1.09.2023</mixed-citation><mixed-citation xml:lang="zh">Well-differentiated thyroid cancer. Clinical guidelines. ID 329. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. 2020. Available from: https://cr.minzdrav.gov.ru/recomend/329_1 (In Russ)</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Avram AM, Giovanella L, Greenspan B, et al. SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version. Journal of Nuclear Medicine. 2022;63(6):15N–35N.</mixed-citation><mixed-citation xml:lang="ru">Avram A.M., Giovanella L., Greenspan B., et al. SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version // Journal of Nuclear Medicine. 2022. Vol. 63, N 6. P. 15N–35N.</mixed-citation><mixed-citation xml:lang="zh">Avram AM, Giovanella L, Greenspan B, et al. SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version. Journal of Nuclear Medicine. 2022;63(6):15N–35N.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133. doi: 10.1089/thy.2015.0020</mixed-citation><mixed-citation xml:lang="ru">Haugen B.R., Alexander E.K., Bible K.C., et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer // Thyroid. 2016. Vol. 26, N 1. P. 1–133. doi: 10.1089/thy.2015.0020</mixed-citation><mixed-citation xml:lang="zh">Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133. doi: 10.1089/thy.2015.0020</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Pacini F, Fuhrer D, Elisei R, et al. 2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? European Thyroid Journal. 2022;11(1). doi: 10.1530/etj-21-0046</mixed-citation><mixed-citation xml:lang="ru">Pacini F., Fuhrer D., Elisei R., et al. 2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? // European Thyroid Journal. 2022. Vol. 11, N 1. doi: 10.1530/etj-21-0046</mixed-citation><mixed-citation xml:lang="zh">Pacini F, Fuhrer D, Elisei R, et al. 2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? European Thyroid Journal. 2022;11(1). doi: 10.1530/etj-21-0046</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2019;30(12):1856–1883. doi: 10.1093/annonc/mdz400</mixed-citation><mixed-citation xml:lang="ru">Filetti S., Durante C., Hartl D., et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Annals of Oncology. 2019. Vol. 30, N 12. P. 1856–1883. doi: 10.1093/annonc/mdz400</mixed-citation><mixed-citation xml:lang="zh">Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2019;30(12):1856–1883. doi: 10.1093/annonc/mdz400</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clinical Endocrinology. 2014;81 Suppl. 1:1–122. doi: 10.1111/cen.12515</mixed-citation><mixed-citation xml:lang="ru">Perros P., Boelaert K., Colley S., et al. Guidelines for the management of thyroid cancer // Clinical Endocrinology. 2014. Vol. 81, Suppl. 1. P. 1–122. doi: 10.1111/cen.12515</mixed-citation><mixed-citation xml:lang="zh">Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clinical Endocrinology. 2014;81 Suppl. 1:1–122. doi: 10.1111/cen.12515</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Haddad RI, Bischoff L, Ball D, et al. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2022;20(8):925–951. doi: 10.6004/jnccn.2022.0040</mixed-citation><mixed-citation xml:lang="ru">Haddad R.I., Bischoff L., Ball D., et al. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology // Journal of the National Comprehensive Cancer Network. 2022. Vol. 20, N 8. P. 925–951. doi: 10.6004/jnccn.2022.0040</mixed-citation><mixed-citation xml:lang="zh">Haddad RI, Bischoff L, Ball D, et al. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2022;20(8):925–951. doi: 10.6004/jnccn.2022.0040</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Golger A, Fridman TR, Eski S, et al. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma. Journal of Endocrinological Investigation. 2003;26(10):1023–1031. doi: 10.1007/bf03348202</mixed-citation><mixed-citation xml:lang="ru">Golger A., Fridman T.R., Eski S., et al. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma // Journal of Endocrinological Investigation. 2003. Vol. 26, N 10. P. 1023–1031. doi: 10.1007/bf03348202</mixed-citation><mixed-citation xml:lang="zh">Golger A, Fridman TR, Eski S, et al. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma. Journal of Endocrinological Investigation. 2003;26(10):1023–1031. doi: 10.1007/bf03348202</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Davids T, Witterick IJ, Eski S, et al. Three-Week Thyroxine Withdrawal: A Thyroid-Specific Quality of Life Study. The Laryngoscope. 2006;116(2):250–253. doi: 10.1097/01.mlg.0000192172.61889.43</mixed-citation><mixed-citation xml:lang="ru">Davids T., Witterick I.J., Eski S., et al. Three-Week Thyroxine Withdrawal: A Thyroid-Specific Quality of Life Study // The Laryngoscope. 2006. Vol. 116, N 2. P. 250–253. doi: 10.1097/01.mlg.0000192172.61889.43</mixed-citation><mixed-citation xml:lang="zh">Davids T, Witterick IJ, Eski S, et al. Three-Week Thyroxine Withdrawal: A Thyroid-Specific Quality of Life Study. The Laryngoscope. 2006;116(2):250–253. doi: 10.1097/01.mlg.0000192172.61889.43</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Lee J, Yun MJ, Nam KH, et al. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid. 2010;20:173–179. doi: 10.1089/thy.2009.0187</mixed-citation><mixed-citation xml:lang="ru">Lee J., Yun M.J., Nam K.H., et al. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma // Thyroid. 2010. 2010. Vol 20. P. 173-179. doi: 10.1089/thy.2009.0187</mixed-citation><mixed-citation xml:lang="zh">Lee J, Yun MJ, Nam KH, et al. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid. 2010;20:173–179. doi: 10.1089/thy.2009.0187</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Leboeuf R, Perron P, Carpentier AC, Verreault J, Langlois MF. L-T3 preparation for whole-body scintigraphy: a randomized-controlled trial. Clinical Endocrinology. 2007;67(6):839–844. doi: 10.1111/j.1365-2265.2007.02972.x</mixed-citation><mixed-citation xml:lang="ru">Leboeuf R., Perron P., Carpentier A.C., Verreault J., Langlois M.F. L-T3 preparation for whole-body scintigraphy: a randomized-controlled trial // Clinical Endocrinology. 2007. Vol. 67, N 6. P. 839–844. doi: 10.1111/j.1365-2265.2007.02972.x</mixed-citation><mixed-citation xml:lang="zh">Leboeuf R, Perron P, Carpentier AC, Verreault J, Langlois MF. L-T3 preparation for whole-body scintigraphy: a randomized-controlled trial. Clinical Endocrinology. 2007;67(6):839–844. doi: 10.1111/j.1365-2265.2007.02972.x</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Rajamanickam S, Chaukar D, Siddiq S, Basu S, D’Cruz A. Quality of life comparison in thyroxine hormone withdrawal versus triiodothyronine supplementation prior to radioiodine ablation in differentiated thyroid carcinoma: a prospective cohort study in the Indian population. European Archives of Oto-Rhino-Laryngology. 2021;279(4). doi: 10.1007/s00405-021-06948-6</mixed-citation><mixed-citation xml:lang="ru">Rajamanickam S., Chaukar D., Siddiq S., Basu S., D’Cruz A. Quality of life comparison in thyroxine hormone withdrawal versus triiodothyronine supplementation prior to radioiodine ablation in differentiated thyroid carcinoma: a prospective cohort study in the Indian population // European Archives of Oto-Rhino-Laryngology. 2021. Vol. 279, N 4. doi: 10.1007/s00405-021-06948-6</mixed-citation><mixed-citation xml:lang="zh">Rajamanickam S, Chaukar D, Siddiq S, Basu S, D’Cruz A. Quality of life comparison in thyroxine hormone withdrawal versus triiodothyronine supplementation prior to radioiodine ablation in differentiated thyroid carcinoma: a prospective cohort study in the Indian population. European Archives of Oto-Rhino-Laryngology. 2021;279(4). doi: 10.1007/s00405-021-06948-6</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Luna R, Penín M, Seoane I, et al. ¿Es necesario suspender durante 4 semanas el tratamiento con tiroxina antes de la realización de un rastreo-ablación? Endocrinología y Nutrición. 2012;59(4):227–231. (In Spanish). doi: 10.1016/j.endonu.2012.02.004</mixed-citation><mixed-citation xml:lang="ru">Luna R., Penín M., Seoane I., et al. ¿Es necesario suspender durante 4 semanas el tratamiento con tiroxina antes de la realización de un rastreo-ablación? // Endocrinología y Nutrición. 2012. Vol. 59, N 4. P. 227–231. (In Spanish) doi: 10.1016/j.endonu.2012.02.004</mixed-citation><mixed-citation xml:lang="zh">Luna R, Penín M, Seoane I, et al. ¿Es necesario suspender durante 4 semanas el tratamiento con tiroxina antes de la realización de un rastreo-ablación? Endocrinología y Nutrición. 2012;59(4):227–231. (In Spanish). doi: 10.1016/j.endonu.2012.02.004</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid. 1997;7(4):613–619. doi: 10.1089/thy.1997.7.613</mixed-citation><mixed-citation xml:lang="ru">Dow K.H., Ferrell B.R., Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy // Thyroid. 1997. Vol. 7, N 4. P. 613–619. doi: 10.1089/thy.1997.7.613</mixed-citation><mixed-citation xml:lang="zh">Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid. 1997;7(4):613–619. doi: 10.1089/thy.1997.7.613</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Liel Y. Preparation for radioactive iodine administration in differentiated thyroid cancer patients. Clinical Endocrinology. 2002;57(4):523–527. doi: 10.1046/j.1365-2265.2002.01631.x</mixed-citation><mixed-citation xml:lang="ru">Liel Y. Preparation for radioactive iodine administration in differentiated thyroid cancer patients // Clinical Endocrinology. 2002. Vol. 57, N 4. P. 523–527. doi: 10.1046/j.1365-2265.2002.01631.x</mixed-citation><mixed-citation xml:lang="zh">Liel Y. Preparation for radioactive iodine administration in differentiated thyroid cancer patients. Clinical Endocrinology. 2002;57(4):523–527. doi: 10.1046/j.1365-2265.2002.01631.x</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Piccardo A, Puntoni M, Ferrarazzo G, et al. Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients? European Journal of Nuclear Medicine and Molecular Imaging. 2018;45(7):1218–1223. doi: 10.1007/s00259-018-3955-x</mixed-citation><mixed-citation xml:lang="ru">Piccardo A., Puntoni M., Ferrarazzo G., et al. Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients? // European Journal of Nuclear Medicine and Molecular Imaging. 2018. Vol. 45, N 7. P. 1218–1223. doi: 10.1007/s00259-018-3955-x</mixed-citation><mixed-citation xml:lang="zh">Piccardo A, Puntoni M, Ferrarazzo G, et al. Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients? European Journal of Nuclear Medicine and Molecular Imaging. 2018;45(7):1218–1223. doi: 10.1007/s00259-018-3955-x</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Santos PA, Flamini ME, Mourato FA, et al. Is a four-week hormone suspension necessary for thyroid remnant ablation in low and intermediate risk patients? A pilot study with quality-of-life assessment. Brazilian Journal of Radiation Sciences. 2022;10(4):1–16. doi:10.15392/2319-0612.2022.2047</mixed-citation><mixed-citation xml:lang="ru">Santos P.A., Flamini M.E., Mourato F.A., et al. Is a four-week hormone suspension necessary for thyroid remnant ablation in low and intermediate risk patients? A pilot study with quality-of-life assessment // Brazilian Journal of Radiation Sciences. 2022. Vol. 10, N 4. P. 1–16. doi:10.15392/2319-0612.2022.2047</mixed-citation><mixed-citation xml:lang="zh">Santos PA, Flamini ME, Mourato FA, et al. Is a four-week hormone suspension necessary for thyroid remnant ablation in low and intermediate risk patients? A pilot study with quality-of-life assessment. Brazilian Journal of Radiation Sciences. 2022;10(4):1–16. doi:10.15392/2319-0612.2022.2047</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Cooper DS, Doherty GM, Haugen BR, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214. doi: 10.1089/thy.2009.0110</mixed-citation><mixed-citation xml:lang="ru">Cooper D.S., Doherty G.M., Haugen B.R., et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer // Thyroid. 2009. Vol. 19, N 11. P. 1167–1214. doi: 10.1089/thy.2009.0110</mixed-citation><mixed-citation xml:lang="zh">Cooper DS, Doherty GM, Haugen BR, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214. doi: 10.1089/thy.2009.0110</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Rosário PW, Vasconcelos FP, Cardoso LD, et al. Managing thyroid cancer without thyroxine withdrawal. Arquivos Brasileiros de Endocrinologia &amp; Metabologia. 2006;50(1):91–96. doi: 10.1590/s0004-27302006000100013</mixed-citation><mixed-citation xml:lang="ru">Rosário P.W., Vasconcelos F.P., Cardoso L.D., et al. Managing thyroid cancer without thyroxine withdrawal // Arquivos Brasileiros de Endocrinologia &amp; Metabologia. 2006. Vol. 50, N 1. P. 91–96. doi: 10.1590/s0004-27302006000100013</mixed-citation><mixed-citation xml:lang="zh">Rosário PW, Vasconcelos FP, Cardoso LD, et al. Managing thyroid cancer without thyroxine withdrawal. Arquivos Brasileiros de Endocrinologia &amp; Metabologia. 2006;50(1):91–96. doi: 10.1590/s0004-27302006000100013</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Edmonds CJ, Hayes S, Kermode JC, Thompson BD. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. The British Journal of Radiology. 1977;50(599):799–807. doi: 10.1259/0007-1285-50-599-799</mixed-citation><mixed-citation xml:lang="ru">Edmonds C.J., Hayes S., Kermode J.C., Thompson B.D. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine // The British Journal of Radiology. 1977. Vol. 50, N 599. P. 799–807. doi: 10.1259/0007-1285-50-599-799</mixed-citation><mixed-citation xml:lang="zh">Edmonds CJ, Hayes S, Kermode JC, Thompson BD. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. The British Journal of Radiology. 1977;50(599):799–807. doi: 10.1259/0007-1285-50-599-799</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Giovanella L, Piccardo A. A “new/old method” for TSH stimulation: could a third way to prepare DTC patients for 131I remnant ablation possibly exist? European Journal of Nuclear Medicine and Molecular Imaging. 2015;43(2):221–223. doi:10.1007/s00259-015-3245-9</mixed-citation><mixed-citation xml:lang="ru">Giovanella L., Piccardo A. A “new/old method” for TSH stimulation: could a third way to prepare DTC patients for 131I remnant ablation possibly exist? // European Journal of Nuclear Medicine and Molecular Imaging. 2015. Vol. 43, N 2. P. 221–223. doi:10.1007/s00259-015-3245-9</mixed-citation><mixed-citation xml:lang="zh">Giovanella L, Piccardo A. A “new/old method” for TSH stimulation: could a third way to prepare DTC patients for 131I remnant ablation possibly exist? European Journal of Nuclear Medicine and Molecular Imaging. 2015;43(2):221–223. doi:10.1007/s00259-015-3245-9</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Semenov DYu, Boriskova ME, Farafonova UV, et al. Prognostic value of Sodium-Iodide Symporter (NIS) in differentiated thyroid cancer. Clinical and experimental thyroidology. 2015;11(1):50. (In Russ). doi: 10.14341/ket2015150-58</mixed-citation><mixed-citation xml:lang="ru">Семенов Д.Ю., Борискова М.Е., Фарафонова У.В., и др. Прогностическое значение экспрессии натрий-йодного симпортера для высокодифференцированного рака щитовидной железы // Клиническая и экспериментальная тиреоидология. 2015. Т. 11, № 1. С. 50. doi: 10.14341/ket2015150-58</mixed-citation><mixed-citation xml:lang="zh">Semenov DYu, Boriskova ME, Farafonova UV, et al. Prognostic value of Sodium-Iodide Symporter (NIS) in differentiated thyroid cancer. Clinical and experimental thyroidology. 2015;11(1):50. (In Russ). doi: 10.14341/ket2015150-58</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Xiao J, Yun C, Cao J, et al. A pre-ablative thyroid-stimulating hormone with 30-70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients. Scientific Reports. 2021;11(1). doi: 10.1038/s41598-020-80015-8</mixed-citation><mixed-citation xml:lang="ru">Xiao J., Yun C., Cao J., et al. A pre-ablative thyroid-stimulating hormone with 30-70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients // Scientific Reports. 2021. Vol. 11, N 1. doi: 10.1038/s41598-020-80015-8</mixed-citation><mixed-citation xml:lang="zh">Xiao J, Yun C, Cao J, et al. A pre-ablative thyroid-stimulating hormone with 30-70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients. Scientific Reports. 2021;11(1). doi: 10.1038/s41598-020-80015-8</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Zhao T, Liang J, Guo Z, Li T, Lin Y. In Patients with Low- to Intermediate-Risk Thyroid Cancer, a Preablative Thyrotropin Level of 30 μIU/mL Is Not Adequate to Achieve Better Response to 131I Therapy. Clinical Nuclear Medicine. 2016;41(6):454–458. doi:10.1097/rlu.0000000000001167</mixed-citation><mixed-citation xml:lang="ru">Zhao T., Liang J., Guo Z., Li T., Lin Y. In Patients with Low- to Intermediate-Risk Thyroid Cancer, a Preablative Thyrotropin Level of 30 μIU/mL Is Not Adequate to Achieve Better Response to 131I Therapy // Clinical Nuclear Medicine. 2016. Vol. 41, N 6. P. 454–458. doi:10.1097/rlu.0000000000001167</mixed-citation><mixed-citation xml:lang="zh">Zhao T, Liang J, Guo Z, Li T, Lin Y. In Patients with Low- to Intermediate-Risk Thyroid Cancer, a Preablative Thyrotropin Level of 30 μIU/mL Is Not Adequate to Achieve Better Response to 131I Therapy. Clinical Nuclear Medicine. 2016;41(6):454–458. doi:10.1097/rlu.0000000000001167</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">Hasbek Z, Turgut B. Is Very High Thyroid Stimulating Hormone Level Required in Differentiated Thyroid Cancer for Ablation Success? Molecular Imaging and Radionuclide Therapy. 2016;25(2):79–84. doi: 10.4274/mirt.88598</mixed-citation><mixed-citation xml:lang="ru">Hasbek Z., Turgut B. Is Very High Thyroid Stimulating Hormone Level Required in Differentiated Thyroid Cancer for Ablation Success? // Molecular Imaging and Radionuclide Therapy. 2016. Vol. 25, N 2. P. 79–84. doi: 10.4274/mirt.88598</mixed-citation><mixed-citation xml:lang="zh">Hasbek Z, Turgut B. Is Very High Thyroid Stimulating Hormone Level Required in Differentiated Thyroid Cancer for Ablation Success? Molecular Imaging and Radionuclide Therapy. 2016;25(2):79–84. doi: 10.4274/mirt.88598</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">Vrachimis A, Riemann B, Mäder U, Reiners C, Verburg FA. Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality. European Journal of Nuclear Medicine and Molecular Imaging. 2016;43(2):224–231. doi: 10.1007/s00259-015-3223-2</mixed-citation><mixed-citation xml:lang="ru">Vrachimis A., Riemann B., Mäder U., Reiners C., Verburg F.A. Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality // European Journal of Nuclear Medicine and Molecular Imaging. 2016. Vol. 43, N 2. P. 224–231. doi:10.1007/s00259-015-3223-2</mixed-citation><mixed-citation xml:lang="zh">Vrachimis A, Riemann B, Mäder U, Reiners C, Verburg FA. Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality. European Journal of Nuclear Medicine and Molecular Imaging. 2016;43(2):224–231. doi: 10.1007/s00259-015-3223-2</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">Montesano T, Durante C, Attard M, et al. Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer. Biomedicine &amp; Pharmacotherapy. 2007;61(8):468–471. doi: 10.1016/j.biopha.2007.04.001</mixed-citation><mixed-citation xml:lang="ru">Montesano T., Durante C., Attard M., et al. Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer // Biomedicine &amp; Pharmacotherapy. 2007. Vol. 61, N 8. P. 468–471. doi: 10.1016/j.biopha.2007.04.001</mixed-citation><mixed-citation xml:lang="zh">Montesano T, Durante C, Attard M, et al. Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer. Biomedicine &amp; Pharmacotherapy. 2007;61(8):468–471. doi: 10.1016/j.biopha.2007.04.001</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">Ju N, Hou L, Song H, et al. TSH ≥30 mU/L may not be necessary for successful 131I remnant ablation in patients with differentiated thyroid cancer. European Thyroid Journal. 2023;12(4). doi: 10.1530/ETJ-22-0219</mixed-citation><mixed-citation xml:lang="ru">Ju N., Hou L., Song H., et al. TSH ≥30 mU/L may not be necessary for successful 131I remnant ablation in patients with differentiated thyroid cancer // European Thyroid Journal. 2023. Vol. 12, N 4. doi: 10.1530/ETJ-22-0219</mixed-citation><mixed-citation xml:lang="zh">Ju N, Hou L, Song H, et al. TSH ≥30 mU/L may not be necessary for successful 131I remnant ablation in patients with differentiated thyroid cancer. European Thyroid Journal. 2023;12(4). doi: 10.1530/ETJ-22-0219</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><citation-alternatives><mixed-citation xml:lang="en">Ren B, Zhu Y. A New Perspective on Thyroid Hormones: Crosstalk with Reproductive Hormones in Females. International Journal of Molecular Sciences. 2022;23(5):2708. doi: 10.3390/ijms23052708</mixed-citation><mixed-citation xml:lang="ru">Ren B., Zhu Y. A New Perspective on Thyroid Hormones: Crosstalk with Reproductive Hormones in Females // International Journal of Molecular Sciences. 2022. Vol. 23, N 5. P. 2708. doi: 10.3390/ijms23052708</mixed-citation><mixed-citation xml:lang="zh">Ren B, Zhu Y. A New Perspective on Thyroid Hormones: Crosstalk with Reproductive Hormones in Females. International Journal of Molecular Sciences. 2022;23(5):2708. doi: 10.3390/ijms23052708</mixed-citation></citation-alternatives></ref><ref id="B36"><label>36.</label><citation-alternatives><mixed-citation xml:lang="en">Rubio GA, Catanuto P, Glassberg MK, Lew JI, Elliot SJ. Estrogen receptor subtype expression and regulation is altered in papillary thyroid cancer after menopause. Surgery. 2018;163(1):143–149. doi: 10.1016/j.surg.2017.04.031</mixed-citation><mixed-citation xml:lang="ru">Rubio G.A., Catanuto P., Glassberg M.K., Lew J.I., Elliot S.J. Estrogen receptor subtype expression and regulation is altered in papillary thyroid cancer after menopause // Surgery. 2018. Vol. 163, N 1. P. 143–149. doi: 10.1016/j.surg.2017.04.031</mixed-citation><mixed-citation xml:lang="zh">Rubio GA, Catanuto P, Glassberg MK, Lew JI, Elliot SJ. Estrogen receptor subtype expression and regulation is altered in papillary thyroid cancer after menopause. Surgery. 2018;163(1):143–149. doi: 10.1016/j.surg.2017.04.031</mixed-citation></citation-alternatives></ref><ref id="B37"><label>37.</label><citation-alternatives><mixed-citation xml:lang="en">Derwahl M, Nicula D. Estrogen and its role in thyroid cancer. Endocrine-Related Cancer. 2014;21(5):T273–T283. doi: 10.1530/erc-14-0053</mixed-citation><mixed-citation xml:lang="ru">Derwahl M., Nicula D. Estrogen and its role in thyroid cancer // Endocrine-Related Cancer. 2014. Vol. 21, N 5. P. T273–T283. doi: 10.1530/erc-14-0053</mixed-citation><mixed-citation xml:lang="zh">Derwahl M, Nicula D. Estrogen and its role in thyroid cancer. Endocrine-Related Cancer. 2014;21(5):T273–T283. doi: 10.1530/erc-14-0053</mixed-citation></citation-alternatives></ref><ref id="B38"><label>38.</label><citation-alternatives><mixed-citation xml:lang="en">Rajoria S, Suriano R, Shanmugam A, et al. Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid. 2010;20(1):33–41. doi: 10.1089/thy.2009.0296</mixed-citation><mixed-citation xml:lang="ru">Rajoria S., Suriano R., Shanmugam A., et al. Metastatic phenotype is regulated by estrogen in thyroid cells // Thyroid. 2010. Vol. 20, N 1. P. 33–41. doi: 10.1089/thy.2009.0296</mixed-citation><mixed-citation xml:lang="zh">Rajoria S, Suriano R, Shanmugam A, et al. Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid. 2010;20(1):33–41. doi: 10.1089/thy.2009.0296</mixed-citation></citation-alternatives></ref><ref id="B39"><label>39.</label><citation-alternatives><mixed-citation xml:lang="en">Tala H, Robbins R, Fagin JA, Larson SM, Tuttle RM. Five-year survival is similar thyroid cancer patients with metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. The Journal of Clinical Endocrinology &amp; Metabolism. 2011;96(7):2105–2111. doi: 10.1210/jc.2011-0305</mixed-citation><mixed-citation xml:lang="ru">Tala H., Robbins R., Fagin J.A., Larson S.M., Tuttle R.M. Five-year survival is similar thyroid cancer patients with metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH // The Journal of Clinical Endocrinology &amp; Metabolism. 2011. Vol. 96, N 7. P. 2105–2111. doi: 10.1210/jc.2011-0305</mixed-citation><mixed-citation xml:lang="zh">Tala H, Robbins R, Fagin JA, Larson SM, Tuttle RM. Five-year survival is similar thyroid cancer patients with metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. The Journal of Clinical Endocrinology &amp; Metabolism. 2011;96(7):2105–2111. doi: 10.1210/jc.2011-0305</mixed-citation></citation-alternatives></ref><ref id="B40"><label>40.</label><citation-alternatives><mixed-citation xml:lang="en">Rosario PW, Mourão GF, Calsolari MR. Recombinant human TSH versus thyroid hormone withdrawal in adjuvant therapy with radioactive iodine of patients with papillary thyroid carcinoma and clinically apparent lymph node metastases not limited to the central compartment (cN1b). Archives of Endocrinology and Metabolism. 2017;61(2):167–172. doi:10.1590/2359-3997000000247</mixed-citation><mixed-citation xml:lang="ru">Rosario P.W., Mourão G.F., Calsolari M.R. Recombinant human TSH versus thyroid hormone withdrawal in adjuvant therapy with radioactive iodine of patients with papillary thyroid carcinoma and clinically apparent lymph node metastases not limited to the central compartment (cN1b) // Archives of Endocrinology and Metabolism. 2017. Vol. 61, N 2. P. 167–172. doi:10.1590/2359-3997000000247</mixed-citation><mixed-citation xml:lang="zh">Rosario PW, Mourão GF, Calsolari MR. Recombinant human TSH versus thyroid hormone withdrawal in adjuvant therapy with radioactive iodine of patients with papillary thyroid carcinoma and clinically apparent lymph node metastases not limited to the central compartment (cN1b). Archives of Endocrinology and Metabolism. 2017;61(2):167–172. doi:10.1590/2359-3997000000247</mixed-citation></citation-alternatives></ref><ref id="B41"><label>41.</label><citation-alternatives><mixed-citation xml:lang="en">Hugo J, Robenshtok E, Grewal R, Larson S, Tuttle RM. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. Thyroid. 2012;22(10):1007–1015. doi: 10.1089/thy.2012.0183</mixed-citation><mixed-citation xml:lang="ru">Hugo J., Robenshtok E., Grewal R., Larson S., Tuttle R.M. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence // Thyroid. 2012. Vol. 22, N 10. P. 1007–1015. doi: 10.1089/thy.2012.0183</mixed-citation><mixed-citation xml:lang="zh">Hugo J, Robenshtok E, Grewal R, Larson S, Tuttle RM. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. Thyroid. 2012;22(10):1007–1015. doi: 10.1089/thy.2012.0183</mixed-citation></citation-alternatives></ref><ref id="B42"><label>42.</label><citation-alternatives><mixed-citation xml:lang="en">Robenshtok E, Tuttle RM. Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer. Indian Journal of Surgical Oncology. 2012;3(3):182–189. doi: 10.1007/s13193-011-0115-1</mixed-citation><mixed-citation xml:lang="ru">Robenshtok E., Tuttle R.M. Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer // Indian Journal of Surgical Oncology. 2012. Vol. 3, N 3. P. 182–189. doi: 10.1007/s13193-011-0115-1</mixed-citation><mixed-citation xml:lang="zh">Robenshtok E, Tuttle RM. Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer. Indian Journal of Surgical Oncology. 2012;3(3):182–189. doi: 10.1007/s13193-011-0115-1</mixed-citation></citation-alternatives></ref><ref id="B43"><label>43.</label><citation-alternatives><mixed-citation xml:lang="en">Higuchi CRS, Fernanda P, Jurnior PA, et al. Clinical Outcomes After Radioiodine Therapy, According to the Method of Preparation by Recombinant TSH vs. Endogenous Hypothyroidism, in Thyroid Cancer Patients at Intermediate-High Risk of Recurrence. Frontiers in Nuclear Medicine. 2021;1. doi: 10.3389/fnume.2021.785768</mixed-citation><mixed-citation xml:lang="ru">Higuchi C.R.S., Fernanda P., Jurnior P.A., et al. Clinical Outcomes After Radioiodine Therapy, According to the Method of Preparation by Recombinant TSH vs. Endogenous Hypothyroidism, in Thyroid Cancer Patients at Intermediate-High Risk of Recurrence // Frontiers in Nuclear Medicine. 2021. Vol. 1. doi: 10.3389/fnume.2021.785768</mixed-citation><mixed-citation xml:lang="zh">Higuchi CRS, Fernanda P, Jurnior PA, et al. Clinical Outcomes After Radioiodine Therapy, According to the Method of Preparation by Recombinant TSH vs. Endogenous Hypothyroidism, in Thyroid Cancer Patients at Intermediate-High Risk of Recurrence. Frontiers in Nuclear Medicine. 2021;1. doi: 10.3389/fnume.2021.785768</mixed-citation></citation-alternatives></ref><ref id="B44"><label>44.</label><citation-alternatives><mixed-citation xml:lang="en">Lawhn-Heath C, Flavell RR, Chuang EY, Liu C. Failure of iodine uptake in microscopic pulmonary metastases after recombinant human thyroid-stimulating hormone stimulation. World Journal of Nuclear Medicine. 2020;19(1):61–64. doi: 10.4103/wjnm.WJNM_29_19</mixed-citation><mixed-citation xml:lang="ru">Lawhn-Heath C., Flavell R.R., Chuang E.Y., Liu C. Failure of iodine uptake in microscopic pulmonary metastases after recombinant human thyroid-stimulating hormone stimulation // World Journal of Nuclear Medicine. 2020. Vol. 19, N 1. P. 61–64. doi: 10.4103/wjnm.WJNM_29_19</mixed-citation><mixed-citation xml:lang="zh">Lawhn-Heath C, Flavell RR, Chuang EY, Liu C. Failure of iodine uptake in microscopic pulmonary metastases after recombinant human thyroid-stimulating hormone stimulation. World Journal of Nuclear Medicine. 2020;19(1):61–64. doi: 10.4103/wjnm.WJNM_29_19</mixed-citation></citation-alternatives></ref><ref id="B45"><label>45.</label><citation-alternatives><mixed-citation xml:lang="en">Lee H, Paeng JC, Choi H, et al. Effect of TSH stimulation protocols on adequacy of low-iodine diet for radioiodine administration. PLoS One. 2021;16(9):e0256727. doi: 10.1371/journal.pone.0256727</mixed-citation><mixed-citation xml:lang="ru">Lee H., Paeng J.C., Choi H., et al. Effect of TSH stimulation protocols on adequacy of low-iodine diet for radioiodine administration // PLoS One. 2021. Vol. 16, N 9. P. e0256727. doi: 10.1371/journal.pone.0256727</mixed-citation><mixed-citation xml:lang="zh">Lee H, Paeng JC, Choi H, et al. Effect of TSH stimulation protocols on adequacy of low-iodine diet for radioiodine administration. PLoS One. 2021;16(9):e0256727. doi: 10.1371/journal.pone.0256727</mixed-citation></citation-alternatives></ref><ref id="B46"><label>46.</label><citation-alternatives><mixed-citation xml:lang="en">Driedger AA, Kotowycz N. Two Cases of Thyroid Carcinoma That Were Not Stimulated by Recombinant Human Thyrotropin. The Journal of Clinical Endocrinology &amp; Metabolism. 2004;89(2):585–590. doi: 10.1210/jc.2003-031650</mixed-citation><mixed-citation xml:lang="ru">Driedger A.A., Kotowycz N. Two Cases of Thyroid Carcinoma That Were Not Stimulated by Recombinant Human Thyrotropin // The Journal of Clinical Endocrinology &amp; Metabolism. 2004. Vol. 89, N 2. P. 585–590. doi: 10.1210/jc.2003-031650</mixed-citation><mixed-citation xml:lang="zh">Driedger AA, Kotowycz N. Two Cases of Thyroid Carcinoma That Were Not Stimulated by Recombinant Human Thyrotropin. The Journal of Clinical Endocrinology &amp; Metabolism. 2004;89(2):585–590. doi: 10.1210/jc.2003-031650</mixed-citation></citation-alternatives></ref><ref id="B47"><label>47.</label><citation-alternatives><mixed-citation xml:lang="en">Mernagh P, Campbell S, Dietlein M, et al. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: The German perspective. European Journal of Endocrinology. 2006;155(3):405–414. doi: 10.1530/eje.1.02223</mixed-citation><mixed-citation xml:lang="ru">Mernagh P., Campbell S., Dietlein M., et al. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: The German perspective // European Journal of Endocrinology. 2006. Vol. 155, N 3. P. 405–414. doi: 10.1530/eje.1.02223</mixed-citation><mixed-citation xml:lang="zh">Mernagh P, Campbell S, Dietlein M, et al. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: The German perspective. European Journal of Endocrinology. 2006;155(3):405–414. doi: 10.1530/eje.1.02223</mixed-citation></citation-alternatives></ref><ref id="B48"><label>48.</label><citation-alternatives><mixed-citation xml:lang="en">Mernagh P, Suebwongpat A, Silverberg J, Weston A. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: The Canadian perspective. Value in Health. 2010;13(3):180–187. doi: 10.1111/j.1524-4733.2009.00650.x</mixed-citation><mixed-citation xml:lang="ru">Mernagh P., Suebwongpat A., Silverberg J., Weston A. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: The Canadian perspective // Value in Health. 2010. Vol. 13, N 3. P. 180–187. doi: 10.1111/j.1524-4733.2009.00650.x</mixed-citation><mixed-citation xml:lang="zh">Mernagh P, Suebwongpat A, Silverberg J, Weston A. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer: The Canadian perspective. Value in Health. 2010;13(3):180–187. doi: 10.1111/j.1524-4733.2009.00650.x</mixed-citation></citation-alternatives></ref><ref id="B49"><label>49.</label><citation-alternatives><mixed-citation xml:lang="en">Borget I, Bonastre J, Catargi B, et al. Quality of life and cost-effectiveness assessment of radioiodine ablation strategies in patients with thyroid cancer: results from the randomized phase III ESTIMABL trial. Journal of Clinical Oncology. 2015;33(26):2885–2892. doi: 10.1200/JCO.2015.61.6722</mixed-citation><mixed-citation xml:lang="ru">Borget I., Bonastre J., Catargi B., et al. Quality of life and cost-effectiveness assessment of radioiodine ablation strategies in patients with thyroid cancer: results from the randomized phase III ESTIMABL trial // Journal of Clinical Oncology. 2015. Vol. 33, N 26. P. 2885–2892. doi: 10.1200/JCO.2015.61.6722</mixed-citation><mixed-citation xml:lang="zh">Borget I, Bonastre J, Catargi B, et al. Quality of life and cost-effectiveness assessment of radioiodine ablation strategies in patients with thyroid cancer: results from the randomized phase III ESTIMABL trial. Journal of Clinical Oncology. 2015;33(26):2885–2892. doi: 10.1200/JCO.2015.61.6722</mixed-citation></citation-alternatives></ref><ref id="B50"><label>50.</label><citation-alternatives><mixed-citation xml:lang="en">Nijhuis TF, van Weperen W, de Klerk JMH. Costs associated with the withdrawal of thyroid hormone suppression therapy during the follow-up treatment of well-differentiated thyroid cancer. Tijdschrift voor nucleaire geneeskunde. 1999;21:98–100.</mixed-citation><mixed-citation xml:lang="ru">Nijhuis T.F., van Weperen W., de Klerk J.M.H. Costs associated with the withdrawal of thyroid hormone suppression therapy during the follow-up treatment of well-differentiated thyroid cancer // Tijdschrift voor nucleaire geneeskunde. 1999. Vol. 21. P. 98–100.</mixed-citation><mixed-citation xml:lang="zh">Nijhuis TF, van Weperen W, de Klerk JMH. Costs associated with the withdrawal of thyroid hormone suppression therapy during the follow-up treatment of well-differentiated thyroid cancer. Tijdschrift voor nucleaire geneeskunde. 1999;21:98–100.</mixed-citation></citation-alternatives></ref><ref id="B51"><label>51.</label><citation-alternatives><mixed-citation xml:lang="en">Vallejo JA, Muros MA. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer treatment in Spanish hospitals. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition). 2017;36(6):362–370. doi: 10.1016/j.remnie.2017.09.001</mixed-citation><mixed-citation xml:lang="ru">Vallejo J.A., Muros M.A. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer treatment in Spanish hospitals // Revista Española de Medicina Nuclear e Imagen Molecular (English Edition). 2017. Vol. 36, N 6. P. 362–370. doi: 10.1016/j.remnie.2017.09.001</mixed-citation><mixed-citation xml:lang="zh">Vallejo JA, Muros MA. Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer treatment in Spanish hospitals. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition). 2017;36(6):362–370. doi: 10.1016/j.remnie.2017.09.001</mixed-citation></citation-alternatives></ref><ref id="B52"><label>52.</label><citation-alternatives><mixed-citation xml:lang="en">Luster M, Felbinger R, Dietlein M, Reiners C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid. 2005;15(10):1147–1155. doi: 10.1089/thy.2005.15.1147</mixed-citation><mixed-citation xml:lang="ru">Luster M., Felbinger R., Dietlein M., Reiners C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration // Thyroid. 2005. Vol. 15, N 10. P. 1147–1155. doi: 10.1089/thy.2005.15.1147</mixed-citation><mixed-citation xml:lang="zh">Luster M, Felbinger R, Dietlein M, Reiners C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid. 2005;15(10):1147–1155. doi: 10.1089/thy.2005.15.1147</mixed-citation></citation-alternatives></ref><ref id="B53"><label>53.</label><citation-alternatives><mixed-citation xml:lang="en">Rosario PW, Xavier AC, Calsolari MR. Recombinant human thyrotropin in thyroid remnant ablation with 131I in high-risk patients. Thyroid. 2010;20(11):1247–1252. doi: 10.1089/thy.2010.0114</mixed-citation><mixed-citation xml:lang="ru">Rosario P.W., Xavier A.C., Calsolari M.R. Recombinant human thyrotropin in thyroid remnant ablation with 131I in high-risk patients // Thyroid. 2010. Vol. 20, N 11. P. 1247–1252. doi: 10.1089/thy.2010.0114</mixed-citation><mixed-citation xml:lang="zh">Rosario PW, Xavier AC, Calsolari MR. Recombinant human thyrotropin in thyroid remnant ablation with 131I in high-risk patients. Thyroid. 2010;20(11):1247–1252. doi: 10.1089/thy.2010.0114</mixed-citation></citation-alternatives></ref><ref id="B54"><label>54.</label><citation-alternatives><mixed-citation xml:lang="en">Iizuka Y, Katagiri T, Ogura K, Inoue M, et al. Comparison of thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone administration for adjuvant therapy in patients with intermediate- to high-risk differentiated thyroid cancer. Annals of Nuclear Medicine. 2020;34(10):736-741. doi: 10.1007/s12149-020-01497-0</mixed-citation><mixed-citation xml:lang="ru">Iizuka Y., Katagiri T., Ogura K., Inoue M., et al. Comparison of thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone administration for adjuvant therapy in patients with intermediate- to high-risk differentiated thyroid cancer // Annals of Nuclear Medicine. 2020. Vol 34, N 10. P. 736–741. doi: 10.1007/s12149-020-01497-0</mixed-citation><mixed-citation xml:lang="zh">Iizuka Y, Katagiri T, Ogura K, Inoue M, et al. Comparison of thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone administration for adjuvant therapy in patients with intermediate- to high-risk differentiated thyroid cancer. Annals of Nuclear Medicine. 2020;34(10):736-741. doi: 10.1007/s12149-020-01497-0</mixed-citation></citation-alternatives></ref><ref id="B55"><label>55.</label><citation-alternatives><mixed-citation xml:lang="en">Robbins RJ, Driedger A, Magner J; The U.S. and Canadian Thyrogen Compassionate Use Program Investigator Group. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid. 2006;16(11):1121–1130. doi: 10.1089/thy.2006.16.1121</mixed-citation><mixed-citation xml:lang="ru">Robbins R.J., Driedger A., Magner J.; The U.S. and Canadian Thyrogen Compassionate Use Program Investigator Group. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine // Thyroid. 2006. Vol. 16, N 11. P. 1121–1130. doi: 10.1089/thy.2006.16.1121</mixed-citation><mixed-citation xml:lang="zh">Robbins RJ, Driedger A, Magner J; The U.S. and Canadian Thyrogen Compassionate Use Program Investigator Group. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid. 2006;16(11):1121–1130. doi: 10.1089/thy.2006.16.1121</mixed-citation></citation-alternatives></ref><ref id="B56"><label>56.</label><citation-alternatives><mixed-citation xml:lang="en">Tu J, Wang S, Huo Z, et al. Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis. Radiotherapy and Oncology. 2014;110(1):25–30. doi: 10.1016/j.radonc.2013.12.018</mixed-citation><mixed-citation xml:lang="ru">Tu J., Wang S., Huo Z., et al. Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis // Radiotherapy and Oncology. 2014. Vol. 110, N 1. P. 25–30. doi: 10.1016/j.radonc.2013.12.018</mixed-citation><mixed-citation xml:lang="zh">Tu J, Wang S, Huo Z, et al. Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis. Radiotherapy and Oncology. 2014;110(1):25–30. doi: 10.1016/j.radonc.2013.12.018</mixed-citation></citation-alternatives></ref><ref id="B57"><label>57.</label><citation-alternatives><mixed-citation xml:lang="en">Ma C, Xie J, Liu W, et al. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer. Cochrane Database of Systematic Reviews. 2010. doi: 10.1002/14651858.CD008302</mixed-citation><mixed-citation xml:lang="ru">Ma C., Xie J., Liu W., et al. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer // Cochrane Database of Systematic Reviews. 2010. doi: 10.1002/14651858.CD008302</mixed-citation><mixed-citation xml:lang="zh">Ma C, Xie J, Liu W, et al. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer. Cochrane Database of Systematic Reviews. 2010. doi: 10.1002/14651858.CD008302</mixed-citation></citation-alternatives></ref><ref id="B58"><label>58.</label><citation-alternatives><mixed-citation xml:lang="en">Wolfson RM, Rachinsky I, Morrison D, et al. Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive Iodine Treatment of Differentiated Thyroid Cancer with Nodal Metastatic Disease. Journal of Oncology. 2016:1–6. doi: 10.1155/2016/6496750</mixed-citation><mixed-citation xml:lang="ru">Wolfson R.M., Rachinsky I., Morrison D., et al. Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive Iodine Treatment of Differentiated Thyroid Cancer with Nodal Metastatic Disease // Journal of Oncology. 2016. P. 1–6. doi: 10.1155/2016/6496750</mixed-citation><mixed-citation xml:lang="zh">Wolfson RM, Rachinsky I, Morrison D, et al. Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive Iodine Treatment of Differentiated Thyroid Cancer with Nodal Metastatic Disease. Journal of Oncology. 2016:1–6. doi: 10.1155/2016/6496750</mixed-citation></citation-alternatives></ref><ref id="B59"><label>59.</label><citation-alternatives><mixed-citation xml:lang="en">Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, et al. Treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. Thyroid. 2012;22(3):310–317. doi: 10.1089/thy.2011.0235</mixed-citation><mixed-citation xml:lang="ru">Klubo-Gwiezdzinska J., Burman K.D., Van Nostrand D., et al. Treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin // Thyroid. 2012. Vol. 22, N 3. P. 310–317. doi: 10.1089/thy.2011.0235</mixed-citation><mixed-citation xml:lang="zh">Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, et al. Treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. Thyroid. 2012;22(3):310–317. doi: 10.1089/thy.2011.0235</mixed-citation></citation-alternatives></ref><ref id="B60"><label>60.</label><citation-alternatives><mixed-citation xml:lang="en">Wolffenbuttel BH, Coppes MH, Bongaerts AH, Glaudemans AW, Links TP. Unexpected symptoms after rhTSH administration due to occult thyroid carcinoma metastasis. The Netherlands journal of medicine. 2013;71(5):253–256.</mixed-citation><mixed-citation xml:lang="ru">Wolffenbuttel B.H., Coppes M.H., Bongaerts A.H., Glaudemans A.W., Links T.P. Unexpected symptoms after rhTSH administration due to occult thyroid carcinoma metastasis // The Netherlands journal of medicine. 2013. Vol. 71, N 5. P. 253–256.</mixed-citation><mixed-citation xml:lang="zh">Wolffenbuttel BH, Coppes MH, Bongaerts AH, Glaudemans AW, Links TP. Unexpected symptoms after rhTSH administration due to occult thyroid carcinoma metastasis. The Netherlands journal of medicine. 2013;71(5):253–256.</mixed-citation></citation-alternatives></ref><ref id="B61"><label>61.</label><citation-alternatives><mixed-citation xml:lang="en">Tsai HC, Ho KC, Chen SH, et al. Feasibility of Recombinant Human TSH as a Preparation for Radioiodine Therapy in Patients with Distant Metastases from Papillary Thyroid Cancer: Comparison of Long-Term Survival Outcomes with Thyroid Hormone Withdrawal. Diagnostics. 2022;12(1):221 doi: 10.3390/diagnostics12010221</mixed-citation><mixed-citation xml:lang="ru">Tsai H.C., Ho K.C., Chen S.H., et al. Feasibility of Recombinant Human TSH as a Preparation for Radioiodine Therapy in Patients with Distant Metastases from Papillary Thyroid Cancer: Comparison of Long-Term Survival Outcomes with Thyroid Hormone Withdrawal // Diagnostics. 2022. Vol. 12, N 1. P. 221 doi: 10.3390/diagnostics12010221</mixed-citation><mixed-citation xml:lang="zh">Tsai HC, Ho KC, Chen SH, et al. Feasibility of Recombinant Human TSH as a Preparation for Radioiodine Therapy in Patients with Distant Metastases from Papillary Thyroid Cancer: Comparison of Long-Term Survival Outcomes with Thyroid Hormone Withdrawal. Diagnostics. 2022;12(1):221 doi: 10.3390/diagnostics12010221</mixed-citation></citation-alternatives></ref><ref id="B62"><label>62.</label><citation-alternatives><mixed-citation xml:lang="en">Goldberg LD, Ditchek NT. Thyroid carcinoma with spinal cord compression. JAMA: The Journal of the American Medical Association. 1981;245(9):953-954. doi: 10.1001/jama.1981.03310340043025</mixed-citation><mixed-citation xml:lang="ru">Goldberg L.D., Ditchek N.T. Thyroid carcinoma with spinal cord compression // JAMA: The Journal of the American Medical Association. 1981. Vol. 245, N 9. P. 953-954. doi: 10.1001/jama.1981.03310340043025</mixed-citation><mixed-citation xml:lang="zh">Goldberg LD, Ditchek NT. Thyroid carcinoma with spinal cord compression. JAMA: The Journal of the American Medical Association. 1981;245(9):953-954. doi: 10.1001/jama.1981.03310340043025</mixed-citation></citation-alternatives></ref><ref id="B63"><label>63.</label><citation-alternatives><mixed-citation xml:lang="en">Hoelting T, Tezelman S, Siperstein AE, Duh QY, Clark OH. Biphasic effects of thyrotropin on invasion and growth of papillary and follicular thyroid cancer in vitro. Thyroid. 1995;5(1):35–40. doi: 10.1089/thy.1995.5.35</mixed-citation><mixed-citation xml:lang="ru">Hoelting T., Tezelman S., Siperstein A.E., Duh Q.Y., Clark O.H. Biphasic effects of thyrotropin on invasion and growth of papillary and follicular thyroid cancer in vitro // Thyroid. 1995. Vol. 5, N 1. P. 35–40. doi: 10.1089/thy.1995.5.35</mixed-citation><mixed-citation xml:lang="zh">Hoelting T, Tezelman S, Siperstein AE, Duh QY, Clark OH. Biphasic effects of thyrotropin on invasion and growth of papillary and follicular thyroid cancer in vitro. Thyroid. 1995;5(1):35–40. doi: 10.1089/thy.1995.5.35</mixed-citation></citation-alternatives></ref><ref id="B64"><label>64.</label><citation-alternatives><mixed-citation xml:lang="en">Pietz L, Michałek K, Waśko R, et al. Wpływ stymulacji endogennego TSH na wzrost resztkowej objetości tarczycy u chorych po całkowitej tyreoidektomii z powodu raka zróznicowanego tarczycy. Endokrynologia Polska. 2008;59:119–122. (In Polish)</mixed-citation><mixed-citation xml:lang="ru">Pietz L., Michałek K., Waśko R., et al. Wpływ stymulacji endogennego TSH na wzrost resztkowej objetości tarczycy u chorych po całkowitej tyreoidektomii z powodu raka zróznicowanego tarczycy // Endokrynologia Polska. 2008. Vol. 59. P. 119–122. (In Polish).</mixed-citation><mixed-citation xml:lang="zh">Pietz L, Michałek K, Waśko R, et al. Wpływ stymulacji endogennego TSH na wzrost resztkowej objetości tarczycy u chorych po całkowitej tyreoidektomii z powodu raka zróznicowanego tarczycy. Endokrynologia Polska. 2008;59:119–122. (In Polish)</mixed-citation></citation-alternatives></ref><ref id="B65"><label>65.</label><citation-alternatives><mixed-citation xml:lang="en">Dedov II, Rumyantsev PO, Nizhegorodova KS, et al. Recombinant human thyrotropin in radioiodine diagnostics and radioiodine ablation of patients with well-differentiated thyroid cancer: the first experience in Russia. Endocrine Surgery. 2018;12(3):128–139. (In Russ). doi: 10.14341/serg9806</mixed-citation><mixed-citation xml:lang="ru">Дедов И.И., Румянцев П.О., Нижегородова К.С., и др. Первый отечественный опыт применения рекомбинантного человеческого тиреотропного гормона при подготовке больных высокодифференцированным раком щитовидной железы к радиойоддиагностике и радиойодаблации // Эндокринная хирургия. 2018. Т. 12, № 3. С. 128–139. doi: 10.14341/serg9806</mixed-citation><mixed-citation xml:lang="zh">Dedov II, Rumyantsev PO, Nizhegorodova KS, et al. Recombinant human thyrotropin in radioiodine diagnostics and radioiodine ablation of patients with well-differentiated thyroid cancer: the first experience in Russia. Endocrine Surgery. 2018;12(3):128–139. (In Russ). doi: 10.14341/serg9806</mixed-citation></citation-alternatives></ref><ref id="B66"><label>66.</label><citation-alternatives><mixed-citation xml:lang="en">Saracyn M, Lubas A, Bober B, et al. Recombinant human thyrotropin worsens renal cortical perfusion and renal function in patients after total thyroidectomy due to differentiated thyroid cancer. Thyroid. 2020;30(5):653–660. doi: 10.1089/thy.2019.0372</mixed-citation><mixed-citation xml:lang="ru">Saracyn M., Lubas A., Bober B., et al. Recombinant human thyrotropin worsens renal cortical perfusion and renal function in patients after total thyroidectomy due to differentiated thyroid cancer // Thyroid. 2020. Vol. 30, N 5. P. 653–660. doi: 10.1089/thy.2019.0372</mixed-citation><mixed-citation xml:lang="zh">Saracyn M, Lubas A, Bober B, et al. Recombinant human thyrotropin worsens renal cortical perfusion and renal function in patients after total thyroidectomy due to differentiated thyroid cancer. Thyroid. 2020;30(5):653–660. doi: 10.1089/thy.2019.0372</mixed-citation></citation-alternatives></ref><ref id="B67"><label>67.</label><citation-alternatives><mixed-citation xml:lang="en">Chaker L, Razvi S, Bensenor IM, et al. Hypothyroidism. Nature Reviews Disease Primers. 2022;8(1). doi: 10.1038/s41572-022-00357-7</mixed-citation><mixed-citation xml:lang="ru">Chaker L., Razvi S., Bensenor I.M., et al. Hypothyroidism // Nature Reviews Disease Primers. 2022. Vol. 8, N 1. doi: 10.1038/s41572-022-00357-7</mixed-citation><mixed-citation xml:lang="zh">Chaker L, Razvi S, Bensenor IM, et al. Hypothyroidism. Nature Reviews Disease Primers. 2022;8(1). doi: 10.1038/s41572-022-00357-7</mixed-citation></citation-alternatives></ref><ref id="B68"><label>68.</label><citation-alternatives><mixed-citation xml:lang="en">Ortiga-Carvalho TM, Sidhaye AR, Wondisford FE. Thyroid hormone receptors and resistance to thyroid hormone disorders. Nature Reviews Endocrinology. 2014;10(10):582–591. doi: 10.1038/nrendo.2014.143</mixed-citation><mixed-citation xml:lang="ru">Ortiga-Carvalho T.M., Sidhaye A.R., Wondisford F.E. Thyroid hormone receptors and resistance to thyroid hormone disorders // Nature Reviews Endocrinology. 2014. Vol. 10, N 10. P. 582–591. doi: 10.1038/nrendo.2014.143</mixed-citation><mixed-citation xml:lang="zh">Ortiga-Carvalho TM, Sidhaye AR, Wondisford FE. Thyroid hormone receptors and resistance to thyroid hormone disorders. Nature Reviews Endocrinology. 2014;10(10):582–591. doi: 10.1038/nrendo.2014.143</mixed-citation></citation-alternatives></ref><ref id="B69"><label>69.</label><citation-alternatives><mixed-citation xml:lang="en">Lien EA, Nedrebo BG, Varhaug JE, et al. Plasma total homocysteine levels during short-term iatrogenic hypothyroidism. Journal of Clinical Endocrinology and Metabolism. 2000;85(3):1049–1053. doi: 10.1210/jcem.85.3.6439</mixed-citation><mixed-citation xml:lang="ru">Lien E.A., Nedrebo B.G., Varhaug J.E., et al. Plasma total homocysteine levels during short-term iatrogenic hypothyroidism // Journal of Clinical Endocrinology and Metabolism. 2000. Vol. 85, N 3. P. 1049–1053. doi: 10.1210/jcem.85.3.6439</mixed-citation><mixed-citation xml:lang="zh">Lien EA, Nedrebo BG, Varhaug JE, et al. Plasma total homocysteine levels during short-term iatrogenic hypothyroidism. Journal of Clinical Endocrinology and Metabolism. 2000;85(3):1049–1053. doi: 10.1210/jcem.85.3.6439</mixed-citation></citation-alternatives></ref><ref id="B70"><label>70.</label><citation-alternatives><mixed-citation xml:lang="en">Bicikova M, Hampl R, Hill M, et al. Steroids, sex hormone-binding globulin, homocysteine, selected hormones and markers of lipid and carbohydrate metabolism in patients with severe hypothyroidism and their changes following thyroid hormone supplementation. Clinical Chemistry and Laboratory Medicine. 2003;41(3):284–292. doi: 10.1515/CCLM.2003.045</mixed-citation><mixed-citation xml:lang="ru">Bicikova M., Hampl R., Hill M., et al. Steroids, sex hormone-binding globulin, homocysteine, selected hormones and markers of lipid and carbohydrate metabolism in patients with severe hypothyroidism and their changes following thyroid hormone supplementation // Clinical Chemistry and Laboratory Medicine. 2003. Vol. 41, N 3. P. 284–292. doi: 10.1515/CCLM.2003.045</mixed-citation><mixed-citation xml:lang="zh">Bicikova M, Hampl R, Hill M, et al. Steroids, sex hormone-binding globulin, homocysteine, selected hormones and markers of lipid and carbohydrate metabolism in patients with severe hypothyroidism and their changes following thyroid hormone supplementation. Clinical Chemistry and Laboratory Medicine. 2003;41(3):284–292. doi: 10.1515/CCLM.2003.045</mixed-citation></citation-alternatives></ref><ref id="B71"><label>71.</label><citation-alternatives><mixed-citation xml:lang="en">Lee SJ, Lee HY, Lee WW, Kim SE. The effect of recombinant human thyroid stimulating hormone on sustaining liver and renal function in thyroid cancer patients during radioactive iodine therapy. Nuclear Medicine Communications. 2014;35(7):727–732. doi: 10.1097/MNM.0000000000000118</mixed-citation><mixed-citation xml:lang="ru">Lee S.J., Lee H.Y., Lee W.W., Kim S.E. The effect of recombinant human thyroid stimulating hormone on sustaining liver and renal function in thyroid cancer patients during radioactive iodine therapy // Nuclear Medicine Communications. 2014. Vol. 35, N 7. P. 727–732. doi: 10.1097/MNM.0000000000000118</mixed-citation><mixed-citation xml:lang="zh">Lee SJ, Lee HY, Lee WW, Kim SE. The effect of recombinant human thyroid stimulating hormone on sustaining liver and renal function in thyroid cancer patients during radioactive iodine therapy. Nuclear Medicine Communications. 2014;35(7):727–732. doi: 10.1097/MNM.0000000000000118</mixed-citation></citation-alternatives></ref><ref id="B72"><label>72.</label><citation-alternatives><mixed-citation xml:lang="en">Targher G, Montagnana M, Salvagno G, et al. Association between serum TSH, free T4 and serum liver enzyme activities in a large cohort of unselected outpatients. Clinical Endocrinology. 2008;68(3):481–484. doi: 10.1111/j.1365-2265.2007.03068.x</mixed-citation><mixed-citation xml:lang="ru">Targher G., Montagnana M., Salvagno G., et al. Association between serum TSH, free T4 and serum liver enzyme activities in a large cohort of unselected outpatients // Clinical Endocrinology. 2008. Vol. 68, N 3. P. 481–484. doi: 10.1111/j.1365-2265.2007.03068.x</mixed-citation><mixed-citation xml:lang="zh">Targher G, Montagnana M, Salvagno G, et al. Association between serum TSH, free T4 and serum liver enzyme activities in a large cohort of unselected outpatients. Clinical Endocrinology. 2008;68(3):481–484. doi: 10.1111/j.1365-2265.2007.03068.x</mixed-citation></citation-alternatives></ref><ref id="B73"><label>73.</label><citation-alternatives><mixed-citation xml:lang="en">Pearce EN, Wilson PW, Yang Q, Vasan RS, Braverman LE. Thyroid function and lipid subparticle sizes in patients with short-term hypothyroidism and a population-based cohort. The Journal of Clinical Endocrinology &amp; Metabolism. 2008;93(3):888–894. doi: 10.1210/jc.2007-1987</mixed-citation><mixed-citation xml:lang="ru">Pearce E.N., Wilson P.W., Yang Q., Vasan R.S., Braverman L.E. Thyroid function and lipid subparticle sizes in patients with short-term hypothyroidism and a population-based cohort // The Journal of Clinical Endocrinology &amp; Metabolism. 2008. Vol. 93, N 3. P. 888–894. doi: 10.1210/jc.2007-1987</mixed-citation><mixed-citation xml:lang="zh">Pearce EN, Wilson PW, Yang Q, Vasan RS, Braverman LE. Thyroid function and lipid subparticle sizes in patients with short-term hypothyroidism and a population-based cohort. The Journal of Clinical Endocrinology &amp; Metabolism. 2008;93(3):888–894. doi: 10.1210/jc.2007-1987</mixed-citation></citation-alternatives></ref><ref id="B74"><label>74.</label><citation-alternatives><mixed-citation xml:lang="en">Ness GC, Lopez D, Chambers CM, et al. Effects of L-triiodothyronine and the thyromimetic L-94901 on serum lipoprotein levels and hepatic low-density lipoprotein receptor, 3-hydroxy-3- methylglutaryl coenzyme A reductase, and apo A-I gene expression. Biochemical Pharmacology. 1998;56(1):121–129. doi: 10.1016/S0006-2952(98)00119-1</mixed-citation><mixed-citation xml:lang="ru">Ness G.C., Lopez D., Chambers C.M., et al. Effects of L-triiodothyronine and the thyromimetic L-94901 on serum lipoprotein levels and hepatic low-density lipoprotein receptor, 3-hydroxy-3- methylglutaryl coenzyme A reductase, and apo A-I gene expression // Biochemical Pharmacology. 1998. Vol. 56, N 1. P. 121–129. doi: 10.1016/S0006-2952(98)00119-1</mixed-citation><mixed-citation xml:lang="zh">Ness GC, Lopez D, Chambers CM, et al. Effects of L-triiodothyronine and the thyromimetic L-94901 on serum lipoprotein levels and hepatic low-density lipoprotein receptor, 3-hydroxy-3- methylglutaryl coenzyme A reductase, and apo A-I gene expression. Biochemical Pharmacology. 1998;56(1):121–129. doi: 10.1016/S0006-2952(98)00119-1</mixed-citation></citation-alternatives></ref><ref id="B75"><label>75.</label><citation-alternatives><mixed-citation xml:lang="en">Pattaravimonporn N, Chaikijurajai T, Chamroonrat W, Sriphrapradang C. Myxedema Psychosis after Levothyroxine Withdrawal in Radioactive Iodine Treatment of Differentiated Thyroid Cancer: A Case Report. Case Reports in Oncology. 2021;14(3):1596–1600. doi: 10.1159/000520128</mixed-citation><mixed-citation xml:lang="ru">Pattaravimonporn N., Chaikijurajai T., Chamroonrat W., Sriphrapradang C. Myxedema Psychosis after Levothyroxine Withdrawal in Radioactive Iodine Treatment of Differentiated Thyroid Cancer: A Case Report // Case Reports in Oncology. 2021. Vol. 14, N 3. P. 1596–1600. doi: 10.1159/000520128</mixed-citation><mixed-citation xml:lang="zh">Pattaravimonporn N, Chaikijurajai T, Chamroonrat W, Sriphrapradang C. Myxedema Psychosis after Levothyroxine Withdrawal in Radioactive Iodine Treatment of Differentiated Thyroid Cancer: A Case Report. Case Reports in Oncology. 2021;14(3):1596–1600. doi: 10.1159/000520128</mixed-citation></citation-alternatives></ref><ref id="B76"><label>76.</label><citation-alternatives><mixed-citation xml:lang="en">Nagamachi S, Jinnouchi S, Nishii R, et al. Cerebral blood flow abnormalities induced by transient hypothyroidism after thyroidectomy – analysis by tc-99m-HMPAO and SPM96. Annals of Nuclear Medicine. 2004;18(6):469–477. doi: 10.1007/BF02984562</mixed-citation><mixed-citation xml:lang="ru">Nagamachi S., Jinnouchi S., Nishii R., et al. Cerebral blood flow abnormalities induced by transient hypothyroidism after thyroidectomy — analysis by tc-99m-HMPAO and SPM96 // Annals of Nuclear Medicine. 2004. Vol. 18, N 6. P. 469–477. doi: 10.1007/BF02984562</mixed-citation><mixed-citation xml:lang="zh">Nagamachi S, Jinnouchi S, Nishii R, et al. Cerebral blood flow abnormalities induced by transient hypothyroidism after thyroidectomy – analysis by tc-99m-HMPAO and SPM96. Annals of Nuclear Medicine. 2004;18(6):469–477. doi: 10.1007/BF02984562</mixed-citation></citation-alternatives></ref><ref id="B77"><label>77.</label><citation-alternatives><mixed-citation xml:lang="en">Constant EL, De Volder AG, Ivanoiu A, et al. Cerebral blood flow and glucose metabolism in hypothyroidism: a positron emission tomography study. Journal of Clinical Endocrinology and Metabolism. 2001;86(8):3864–3870. doi: 10.1210/jcem.86.8.7749</mixed-citation><mixed-citation xml:lang="ru">Constant E.L., De Volder A.G., Ivanoiu A., et al. Cerebral blood flow and glucose metabolism in hypothyroidism: a positron emission tomography study // Journal of Clinical Endocrinology and Metabolism. 2001. Vol. 86, N 8. P. 3864–3870. doi: 10.1210/jcem.86.8.7749</mixed-citation><mixed-citation xml:lang="zh">Constant EL, De Volder AG, Ivanoiu A, et al. Cerebral blood flow and glucose metabolism in hypothyroidism: a positron emission tomography study. Journal of Clinical Endocrinology and Metabolism. 2001;86(8):3864–3870. doi: 10.1210/jcem.86.8.7749</mixed-citation></citation-alternatives></ref><ref id="B78"><label>78.</label><citation-alternatives><mixed-citation xml:lang="en">Duntas LH, Biondi B. Short-term hypothyroidism after Levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences. European Journal of Endocrinology. 2007;156(1):13–19. doi: 10.1530/eje.1.02310</mixed-citation><mixed-citation xml:lang="ru">Duntas L.H., Biondi B. Short-term hypothyroidism after Levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences // European Journal of Endocrinology. 2007. Vol. 156, N 1. P. 13–19. doi: 10.1530/eje.1.02310</mixed-citation><mixed-citation xml:lang="zh">Duntas LH, Biondi B. Short-term hypothyroidism after Levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences. European Journal of Endocrinology. 2007;156(1):13–19. doi: 10.1530/eje.1.02310</mixed-citation></citation-alternatives></ref><ref id="B79"><label>79.</label><citation-alternatives><mixed-citation xml:lang="en">Kao PF, Lin JD, Chiu CT, et al. Gastric emptying function changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Journal of Gastroenterology and Hepatology. 2004;19(6):655–660. doi: 10.1111/j.1440-1746.2003.03326.x</mixed-citation><mixed-citation xml:lang="ru">Kao P.F., Lin J.D., Chiu C.T., et al. Gastric emptying function changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy // Journal of Gastroenterology and Hepatology. 2004. Vol. 19, N 6. P. 655–660. doi: 10.1111/j.1440-1746.2003.03326.x</mixed-citation><mixed-citation xml:lang="zh">Kao PF, Lin JD, Chiu CT, et al. Gastric emptying function changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Journal of Gastroenterology and Hepatology. 2004;19(6):655–660. doi: 10.1111/j.1440-1746.2003.03326.x</mixed-citation></citation-alternatives></ref><ref id="B80"><label>80.</label><citation-alternatives><mixed-citation xml:lang="en">Botella-Carretero JI, Prados A, Manzano L, et al. The effects of thyroid hormones on circulating markers of cell-mediated immune response, as studied in patients with differentiated thyroid carcinoma before and during thyroxine withdrawal. European Journal of Endocrinology. 2005;153(2):223–230. doi: 10.1530/eje.1.01951</mixed-citation><mixed-citation xml:lang="ru">Botella-Carretero J.I., Prados A., Manzano L., et al. The effects of thyroid hormones on circulating markers of cell-mediated immune response, as studied in patients with differentiated thyroid carcinoma before and during thyroxine withdrawal // European Journal of Endocrinology. 2005. Vol. 153, N 2. P. 223–230. doi: 10.1530/eje.1.01951</mixed-citation><mixed-citation xml:lang="zh">Botella-Carretero JI, Prados A, Manzano L, et al. The effects of thyroid hormones on circulating markers of cell-mediated immune response, as studied in patients with differentiated thyroid carcinoma before and during thyroxine withdrawal. European Journal of Endocrinology. 2005;153(2):223–230. doi: 10.1530/eje.1.01951</mixed-citation></citation-alternatives></ref><ref id="B81"><label>81.</label><citation-alternatives><mixed-citation xml:lang="en">Duranton F, Lacoste A, Faurous P, et al. Exogenous thyrotropin improves renal function in euthyroid patients, while serum creatinine levels are increased in hypothyroidism. Clinical Kidney Journal. 2013;6(5):478–483. doi: 10.1093/ckj/sft092</mixed-citation><mixed-citation xml:lang="ru">Duranton F., Lacoste A., Faurous P., et al. Exogenous thyrotropin improves renal function in euthyroid patients, while serum creatinine levels are increased in hypothyroidism // Clinical Kidney Journal. 2013. Vol. 6, N 5. P. 478–483. doi: 10.1093/ckj/sft092</mixed-citation><mixed-citation xml:lang="zh">Duranton F, Lacoste A, Faurous P, et al. Exogenous thyrotropin improves renal function in euthyroid patients, while serum creatinine levels are increased in hypothyroidism. Clinical Kidney Journal. 2013;6(5):478–483. doi: 10.1093/ckj/sft092</mixed-citation></citation-alternatives></ref><ref id="B82"><label>82.</label><citation-alternatives><mixed-citation xml:lang="en">Coura-Filho GB, Willegaignon J, Buchpiguel CA, Sapienza MT. Effects of thyroid hormone withdrawal and recombinant human thyrotropin on glomerular filtration rate during radioiodine therapy for well-differentiated thyroid cancer. Thyroid. 2015;25(12):1291–1296. doi: 10.1089/thy.2015.0173</mixed-citation><mixed-citation xml:lang="ru">Coura-Filho G.B., Willegaignon J., Buchpiguel C.A., Sapienza M.T. Effects of thyroid hormone withdrawal and recombinant human thyrotropin on glomerular filtration rate during radioiodine therapy for well-differentiated thyroid cancer // Thyroid. 2015. Vol. 25, N 12. P. 1291–1296. doi: 10.1089/thy.2015.0173</mixed-citation><mixed-citation xml:lang="zh">Coura-Filho GB, Willegaignon J, Buchpiguel CA, Sapienza MT. Effects of thyroid hormone withdrawal and recombinant human thyrotropin on glomerular filtration rate during radioiodine therapy for well-differentiated thyroid cancer. Thyroid. 2015;25(12):1291–1296. doi: 10.1089/thy.2015.0173</mixed-citation></citation-alternatives></ref><ref id="B83"><label>83.</label><citation-alternatives><mixed-citation xml:lang="en">An YS, Lee J, Kim HK, Lee SJ, Yoon JK. Effect of withdrawal of thyroid hormones versus administration of recombinant human thyroid-stimulating hormone on renal function in thyroid cancer patients. Scientific Reports. 2023;13(1). doi: 10.1038/s41598-023-27455-0</mixed-citation><mixed-citation xml:lang="ru">An Y.S., Lee J., Kim H.K., Lee S.J., Yoon J.K. Effect of withdrawal of thyroid hormones versus administration of recombinant human thyroid-stimulating hormone on renal function in thyroid cancer patients // Scientific Reports. 2023. Vol. 13, N 1. doi: 10.1038/s41598-023-27455-0</mixed-citation><mixed-citation xml:lang="zh">An YS, Lee J, Kim HK, Lee SJ, Yoon JK. Effect of withdrawal of thyroid hormones versus administration of recombinant human thyroid-stimulating hormone on renal function in thyroid cancer patients. Scientific Reports. 2023;13(1). doi: 10.1038/s41598-023-27455-0</mixed-citation></citation-alternatives></ref><ref id="B84"><label>84.</label><citation-alternatives><mixed-citation xml:lang="en">Den Hollander JG, Wulkan RW, Mantel MJ, Berghout A. Correlation between severity of thyroid dysfunction and renal function. Clinical Endocrinology. 2005;62(4):423–427. doi: 10.1111/j.1365-2265.2005.02236.x</mixed-citation><mixed-citation xml:lang="ru">Den Hollander J.G., Wulkan R.W., Mantel M.J., Berghout A. Correlation between severity of thyroid dysfunction and renal function // Clinical Endocrinology. 2005. Vol. 62, N 4. P. 423–427. doi: 10.1111/j.1365-2265.2005.02236.x</mixed-citation><mixed-citation xml:lang="zh">Den Hollander JG, Wulkan RW, Mantel MJ, Berghout A. Correlation between severity of thyroid dysfunction and renal function. Clinical Endocrinology. 2005;62(4):423–427. doi: 10.1111/j.1365-2265.2005.02236.x</mixed-citation></citation-alternatives></ref><ref id="B85"><label>85.</label><citation-alternatives><mixed-citation xml:lang="en">Cho YY, Kim SK, Jung JH, et al. Long-term outcomes of renal function after radioactive iodine therapy for thyroid cancer according to preparation method: thyroid hormone withdrawal vs. recombinant human thyrotropin. Endocrine. 2019;64(2):293–298. doi: 10.1007/s12020-018-1807-x</mixed-citation><mixed-citation xml:lang="ru">Cho Y.Y., Kim S.K., Jung J.H., et al. Long-term outcomes of renal function after radioactive iodine therapy for thyroid cancer according to preparation method: thyroid hormone withdrawal vs. recombinant human thyrotropin // Endocrine. 2019. Vol. 64, N 2. P. 293–298. doi: 10.1007/s12020-018-1807-x</mixed-citation><mixed-citation xml:lang="zh">Cho YY, Kim SK, Jung JH, et al. Long-term outcomes of renal function after radioactive iodine therapy for thyroid cancer according to preparation method: thyroid hormone withdrawal vs. recombinant human thyrotropin. Endocrine. 2019;64(2):293–298. doi: 10.1007/s12020-018-1807-x</mixed-citation></citation-alternatives></ref><ref id="B86"><label>86.</label><citation-alternatives><mixed-citation xml:lang="en">Kreisman SH, Hennessey JV. Consistent Reversible Elevations of Serum Creatinine Levels in Severe Hypothyroidism. Archives of Internal Medicine. 1999;159(1):79–82. doi: 10.1001/archinte.159.1.79</mixed-citation><mixed-citation xml:lang="ru">Kreisman S.H., Hennessey J.V. Consistent Reversible Elevations of Serum Creatinine Levels in Severe Hypothyroidism // Archives of Internal Medicine. 1999. Vol. 159, N 1. P. 79–82. doi: 10.1001/archinte.159.1.79</mixed-citation><mixed-citation xml:lang="zh">Kreisman SH, Hennessey JV. Consistent Reversible Elevations of Serum Creatinine Levels in Severe Hypothyroidism. Archives of Internal Medicine. 1999;159(1):79–82. doi: 10.1001/archinte.159.1.79</mixed-citation></citation-alternatives></ref><ref id="B87"><label>87.</label><citation-alternatives><mixed-citation xml:lang="en">Mariani LH, Berns JS. The Renal Manifestations of Thyroid Disease. Journal of the American Society of Nephrology. 2012;23(1):22–26. doi: 10.1681/ASN.2010070766</mixed-citation><mixed-citation xml:lang="ru">Mariani L.H., Berns J.S. The Renal Manifestations of Thyroid Disease // Journal of the American Society of Nephrology. 2012. Vol. 23, N 1. P. 22–26. doi: 10.1681/ASN.2010070766</mixed-citation><mixed-citation xml:lang="zh">Mariani LH, Berns JS. The Renal Manifestations of Thyroid Disease. Journal of the American Society of Nephrology. 2012;23(1):22–26. doi: 10.1681/ASN.2010070766</mixed-citation></citation-alternatives></ref><ref id="B88"><label>88.</label><citation-alternatives><mixed-citation xml:lang="en">Kim SK, Yun GY, Kim KH. et al. Severe hyponatremia following radioactive iodine therapy in patients with differentiated thyroid cancer. Thyroid. 2014;24(4):773–777. doi: 10.1089/thy.2013.0110</mixed-citation><mixed-citation xml:lang="ru">Kim S.K., Yun G.Y., Kim K.H. et al. Severe hyponatremia following radioactive iodine therapy in patients with differentiated thyroid cancer // Thyroid. 2014. Vol. 24, N 4. P. 773–777. doi: 10.1089/thy.2013.0110</mixed-citation><mixed-citation xml:lang="zh">Kim SK, Yun GY, Kim KH. et al. Severe hyponatremia following radioactive iodine therapy in patients with differentiated thyroid cancer. Thyroid. 2014;24(4):773–777. doi: 10.1089/thy.2013.0110</mixed-citation></citation-alternatives></ref><ref id="B89"><label>89.</label><citation-alternatives><mixed-citation xml:lang="en">Nozu T, Yoshida Y, Ohira M, Okumura T. Severe hyponatremia in association with I (131) therapy in a patient with metastatic thyroid cancer. Internal Medicine. 2011;50(19):2169–2174. doi: 10.2169/internalmedicine.50.5740</mixed-citation><mixed-citation xml:lang="ru">Nozu T., Yoshida Y., Ohira M., Okumura T. Severe hyponatremia in association with I (131) therapy in a patient with metastatic thyroid cancer // Internal Medicine. 2011. Vol. 50, N 19. P. 2169–2174. doi: 10.2169/internalmedicine.50.5740</mixed-citation><mixed-citation xml:lang="zh">Nozu T, Yoshida Y, Ohira M, Okumura T. Severe hyponatremia in association with I (131) therapy in a patient with metastatic thyroid cancer. Internal Medicine. 2011;50(19):2169–2174. doi: 10.2169/internalmedicine.50.5740</mixed-citation></citation-alternatives></ref><ref id="B90"><label>90.</label><citation-alternatives><mixed-citation xml:lang="en">Shakir MK, Krook LS, Schraml FV, Clyde PW. Symptomatic hyponatremia in association with a low-iodine diet and levothyroxine withdrawal prior to I131 in patients with metastatic thyroid carcinoma. Thyroid. 2008;18(7):787–792. doi: 10.1089/thy.2008.0050</mixed-citation><mixed-citation xml:lang="ru">Shakir M.K., Krook L.S., Schraml F.V., Clyde P.W. Symptomatic hyponatremia in association with a low-iodine diet and levothyroxine withdrawal prior to I131 in patients with metastatic thyroid carcinoma // Thyroid. 2008. Vol. 18, N 7. P. 787–792. doi: 10.1089/thy.2008.0050</mixed-citation><mixed-citation xml:lang="zh">Shakir MK, Krook LS, Schraml FV, Clyde PW. Symptomatic hyponatremia in association with a low-iodine diet and levothyroxine withdrawal prior to I131 in patients with metastatic thyroid carcinoma. Thyroid. 2008;18(7):787–792. doi: 10.1089/thy.2008.0050</mixed-citation></citation-alternatives></ref><ref id="B91"><label>91.</label><citation-alternatives><mixed-citation xml:lang="en">Al Nozha OM, Vautour L, How J. Life-threatening hyponatremia following a low-iodine diet: a case report and review of all reported cases. Endocrine Practice. 2011;17(5):e113–e117. doi: 10.4158/EP11045.CR</mixed-citation><mixed-citation xml:lang="ru">Al Nozha O.M., Vautour L., How J. Life-threatening hyponatremia following a low-iodine diet: a case report and review of all reported cases // Endocrine Practice. 2011. Vol. 17, N 5. P. e113–e117. doi: 10.4158/EP11045.CR</mixed-citation><mixed-citation xml:lang="zh">Al Nozha OM, Vautour L, How J. Life-threatening hyponatremia following a low-iodine diet: a case report and review of all reported cases. Endocrine Practice. 2011;17(5):e113–e117. doi: 10.4158/EP11045.CR</mixed-citation></citation-alternatives></ref><ref id="B92"><label>92.</label><citation-alternatives><mixed-citation xml:lang="en">Lee JE, Kim SK, Han KH, et al. Risk factors for developing hyponatremia in thyroid cancer patients undergoing radioactive iodine therapy. PLoS One. 2014;9(8):e106840. doi: 10.1371/journal.pone.0106840</mixed-citation><mixed-citation xml:lang="ru">Lee J.E., Kim S.K., Han K.H., et al. Risk factors for developing hyponatremia in thyroid cancer patients undergoing radioactive iodine therapy // PLoS One. 2014. Vol. 9, N 8. P. e106840. doi: 10.1371/journal.pone.0106840</mixed-citation><mixed-citation xml:lang="zh">Lee JE, Kim SK, Han KH, et al. Risk factors for developing hyponatremia in thyroid cancer patients undergoing radioactive iodine therapy. PLoS One. 2014;9(8):e106840. doi: 10.1371/journal.pone.0106840</mixed-citation></citation-alternatives></ref><ref id="B93"><label>93.</label><citation-alternatives><mixed-citation xml:lang="en">Horie I, Ando T, Imaizumi M, Usa T, Kawakami A. Hyperkalemia develops in some thyroidectomized patients undergoing thyroid hormone withdrawal in preparation for radioactive iodine ablation for thyroid carcinoma. Endocrine Practice. 2015;21(5):488–494. doi: 10.4158/EP14532.OR</mixed-citation><mixed-citation xml:lang="ru">Horie I., Ando T., Imaizumi M., Usa T., Kawakami A. Hyperkalemia develops in some thyroidectomized patients undergoing thyroid hormone withdrawal in preparation for radioactive iodine ablation for thyroid carcinoma // Endocrine Practice. 2015. Vol. 21, N 5. P. 488–494. doi: 10.4158/EP14532.OR</mixed-citation><mixed-citation xml:lang="zh">Horie I, Ando T, Imaizumi M, Usa T, Kawakami A. Hyperkalemia develops in some thyroidectomized patients undergoing thyroid hormone withdrawal in preparation for radioactive iodine ablation for thyroid carcinoma. Endocrine Practice. 2015;21(5):488–494. doi: 10.4158/EP14532.OR</mixed-citation></citation-alternatives></ref><ref id="B94"><label>94.</label><citation-alternatives><mixed-citation xml:lang="en">Hyer S, Kong A, Pratt B, Harmer C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clinical Oncology. 2007;19(1):83–86. doi: 10.1016/j.clon.2006.11.005</mixed-citation><mixed-citation xml:lang="ru">Hyer S., Kong A., Pratt B., Harmer C. Salivary gland toxicity after radioiodine therapy for thyroid cancer // Clinical Oncology. 2007. Vol. 19, N 1. P. 83–86. doi: 10.1016/j.clon.2006.11.005</mixed-citation><mixed-citation xml:lang="zh">Hyer S, Kong A, Pratt B, Harmer C. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clinical Oncology. 2007;19(1):83–86. doi: 10.1016/j.clon.2006.11.005</mixed-citation></citation-alternatives></ref><ref id="B95"><label>95.</label><citation-alternatives><mixed-citation xml:lang="en">Riachy R, Ghazal N, Haidar MB, Elamine A, Nasrallah MP. Early Sialadenitis After Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Prevalence and Predictors. International Journal of Endocrinology. 2020;2020:1–7. doi: 10.1155/2020/8649794</mixed-citation><mixed-citation xml:lang="ru">Riachy R., Ghazal N., Haidar M.B., Elamine A., Nasrallah M.P. Early Sialadenitis After Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Prevalence and Predictors // International Journal of Endocrinology. 2020. Vol. 2020. P. 1–7. doi: 10.1155/2020/8649794</mixed-citation><mixed-citation xml:lang="zh">Riachy R, Ghazal N, Haidar MB, Elamine A, Nasrallah MP. Early Sialadenitis After Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Prevalence and Predictors. International Journal of Endocrinology. 2020;2020:1–7. doi: 10.1155/2020/8649794</mixed-citation></citation-alternatives></ref><ref id="B96"><label>96.</label><citation-alternatives><mixed-citation xml:lang="en">Adramerinas M, Andreadis D, Vahtsevanos K, Poulopoulos A, Pazaitou-Panayiotou K. Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand? Hormones. 2021;20(4):669–678. doi: 10.1007/s42000-021-00304-3</mixed-citation><mixed-citation xml:lang="ru">Adramerinas M., Andreadis D., Vahtsevanos K., Poulopoulos A., Pazaitou-Panayiotou K. Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand? // Hormones. 2021. Vol. 20, N 4. P. 669–678. doi: 10.1007/s42000-021-00304-3</mixed-citation><mixed-citation xml:lang="zh">Adramerinas M, Andreadis D, Vahtsevanos K, Poulopoulos A, Pazaitou-Panayiotou K. Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand? Hormones. 2021;20(4):669–678. doi: 10.1007/s42000-021-00304-3</mixed-citation></citation-alternatives></ref><ref id="B97"><label>97.</label><citation-alternatives><mixed-citation xml:lang="en">Silberstein E. Prevention of radiation sialadenitis and glossitis after radioiodine-131 therapy of thyroid cancer. Journal of Nuclear Medicine. 2007;48 Suppl. 2.</mixed-citation><mixed-citation xml:lang="ru">Silberstein E. Prevention of radiation sialadenitis and glossitis after radioiodine-131 therapy of thyroid cancer // Journal of Nuclear Medicine. 2007. Vol. 48, Suppl. 2.</mixed-citation><mixed-citation xml:lang="zh">Silberstein E. Prevention of radiation sialadenitis and glossitis after radioiodine-131 therapy of thyroid cancer. Journal of Nuclear Medicine. 2007;48 Suppl. 2.</mixed-citation></citation-alternatives></ref><ref id="B98"><label>98.</label><citation-alternatives><mixed-citation xml:lang="en">Ma C, Xie J, Jiang Z, Wang G, Zuo S. Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2010;37(9):1778–1785. doi: 10.1007/s00259-009-1368-6</mixed-citation><mixed-citation xml:lang="ru">Ma C., Xie J., Jiang Z., Wang G., Zuo S. Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer // European Journal of Nuclear Medicine and Molecular Imaging. 2010. Vol. 37, N 9. P. 1778–1785. doi: 10.1007/s00259-009-1368-6</mixed-citation><mixed-citation xml:lang="zh">Ma C, Xie J, Jiang Z, Wang G, Zuo S. Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2010;37(9):1778–1785. doi: 10.1007/s00259-009-1368-6</mixed-citation></citation-alternatives></ref><ref id="B99"><label>99.</label><citation-alternatives><mixed-citation xml:lang="en">Nakada K, Ishibashi T, Takei T. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? Journal of nuclear medicine. 2005;46(2):261–266.</mixed-citation><mixed-citation xml:lang="ru">Nakada K., Ishibashi T., Takei T. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? // Journal of nuclear medicine. 2005. Vol. 46, N 2. P. 261–266.</mixed-citation><mixed-citation xml:lang="zh">Nakada K, Ishibashi T, Takei T. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? Journal of nuclear medicine. 2005;46(2):261–266.</mixed-citation></citation-alternatives></ref><ref id="B100"><label>100.</label><citation-alternatives><mixed-citation xml:lang="en">Le Roux MK, Graillon N, Guyot L. Salivary side effects after radioiodine treatment for differentiated papillary thyroid carcinoma: Long-term study. Head &amp; Neck. 2020;42(11):3133–3140. doi: 10.1002/hed.26359</mixed-citation><mixed-citation xml:lang="ru">Le Roux M.K., Graillon N., Guyot L. Salivary side effects after radioiodine treatment for differentiated papillary thyroid carcinoma: Long-term study // Head &amp; Neck. 2020. Vol. 42, N 11. P. 3133–3140. doi: 10.1002/hed.26359</mixed-citation><mixed-citation xml:lang="zh">Le Roux MK, Graillon N, Guyot L. Salivary side effects after radioiodine treatment for differentiated papillary thyroid carcinoma: Long-term study. Head &amp; Neck. 2020;42(11):3133–3140. doi: 10.1002/hed.26359</mixed-citation></citation-alternatives></ref><ref id="B101"><label>101.</label><citation-alternatives><mixed-citation xml:lang="en">Jentzen W, Balschuweit D, Schmitz J, et al. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using (124) I PET(/CT) imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2010;37(12):2298–2306. doi: 10.1007/s00259-010-1532-z</mixed-citation><mixed-citation xml:lang="ru">Jentzen W., Balschuweit D., Schmitz J., et al. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using (124) I PET(/CT) imaging // European Journal of Nuclear Medicine and Molecular Imaging. 2010. Vol. 37, N 12. P. 2298–2306. doi: 10.1007/s00259-010-1532-z</mixed-citation><mixed-citation xml:lang="zh">Jentzen W, Balschuweit D, Schmitz J, et al. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using (124) I PET(/CT) imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2010;37(12):2298–2306. doi: 10.1007/s00259-010-1532-z</mixed-citation></citation-alternatives></ref><ref id="B102"><label>102.</label><citation-alternatives><mixed-citation xml:lang="en">Trukhin AA, Yartsev VD, Sheremeta MS, et al. Nasolacrimal Duct Obstruction Secondary to Radioactive Iodine-131 Therapy for Differentiated Thyroid Cancer. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation. 2022;12(4):415–424. doi: 10.30895/1991-2919-2022-12-4-415-424</mixed-citation><mixed-citation xml:lang="ru">Трухин А.А., Ярцев В.Д., Шеремета М.С., и др. Вторичная облитерация слезоотводящих путей при проведении радиойодтерапии 131I дифференцированного рака щитовидной железы // Регуляторные исследования и экспертиза лекарственных средств. 2022. Т. 12, № 4. C. 415–424. doi: 10.30895/1991-2919-2022-12-4-415-424</mixed-citation><mixed-citation xml:lang="zh">Trukhin AA, Yartsev VD, Sheremeta MS, et al. Nasolacrimal Duct Obstruction Secondary to Radioactive Iodine-131 Therapy for Differentiated Thyroid Cancer. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation. 2022;12(4):415–424. doi: 10.30895/1991-2919-2022-12-4-415-424</mixed-citation></citation-alternatives></ref><ref id="B103"><label>103.</label><citation-alternatives><mixed-citation xml:lang="en">Iakovou I, Goulis DG, Tsinaslanidou Z,et al. Effect of recombinant human thyroid-stimulating hormone or levothyroxine withdrawal on salivary gland dysfunction after radioactive iodine administration for thyroid remnant ablation. Head &amp; Neck. 2016;38 Suppl. 1:E227–230. doi: 10.1002/hed.23974</mixed-citation><mixed-citation xml:lang="ru">Iakovou I., Goulis D.G., Tsinaslanidou Z.,et al. Effect of recombinant human thyroid-stimulating hormone or levothyroxine withdrawal on salivary gland dysfunction after radioactive iodine administration for thyroid remnant ablation // Head &amp; Neck. 2016. Vol. 38, Suppl. 1. P. E227–230. doi: 10.1002/hed.23974</mixed-citation><mixed-citation xml:lang="zh">Iakovou I, Goulis DG, Tsinaslanidou Z,et al. Effect of recombinant human thyroid-stimulating hormone or levothyroxine withdrawal on salivary gland dysfunction after radioactive iodine administration for thyroid remnant ablation. Head &amp; Neck. 2016;38 Suppl. 1:E227–230. doi: 10.1002/hed.23974</mixed-citation></citation-alternatives></ref><ref id="B104"><label>104.</label><citation-alternatives><mixed-citation xml:lang="en">Rosario PW, Calsolari MR. Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin. Thyroid. 2013;23(5):617–619. doi: 10.1089/thy.2012.0050</mixed-citation><mixed-citation xml:lang="ru">Rosario P.W., Calsolari M.R. Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin // Thyroid. 2013. Vol. 23, N 5. P. 617–619. doi: 10.1089/thy.2012.0050</mixed-citation><mixed-citation xml:lang="zh">Rosario PW, Calsolari MR. Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin. Thyroid. 2013;23(5):617–619. doi: 10.1089/thy.2012.0050</mixed-citation></citation-alternatives></ref><ref id="B105"><label>105.</label><citation-alternatives><mixed-citation xml:lang="en">Molenaar RJ, Sidana S, Radivoyevitch T, et al. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. Journal of Clinical Oncology. 2018;36(18):1831–1839. doi: 10.1200/JCO.2017.75.0232</mixed-citation><mixed-citation xml:lang="ru">Molenaar R.J., Sidana S., Radivoyevitch T., et al. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer // Journal of Clinical Oncology. 2018. Vol. 36, N 18. P. 1831–1839. doi: 10.1200/JCO.2017.75.0232</mixed-citation><mixed-citation xml:lang="zh">Molenaar RJ, Sidana S, Radivoyevitch T, et al. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. Journal of Clinical Oncology. 2018;36(18):1831–1839. doi: 10.1200/JCO.2017.75.0232</mixed-citation></citation-alternatives></ref><ref id="B106"><label>106.</label><citation-alternatives><mixed-citation xml:lang="en">Signore A, Campagna G, Marinaccio J, et al. Analysis of Short-Term and Stable DNA Damage in Patients with Differentiated Thyroid Cancer Treated with 131I in Hypothyroidism or with Recombinant Human Thyroid-Stimulating Hormone for Remnant Ablation. Journal of Nuclear Medicine. 2022;63(10):1515–1522. doi: 10.2967/jnumed.121.263442</mixed-citation><mixed-citation xml:lang="ru">Signore A., Campagna G., Marinaccio J., et al. Analysis of Short-Term and Stable DNA Damage in Patients with Differentiated Thyroid Cancer Treated with 131I in Hypothyroidism or with Recombinant Human Thyroid-Stimulating Hormone for Remnant Ablation // Journal of Nuclear Medicine. 2022. Vol. 63, N 10. P. 1515–1522. doi: 10.2967/jnumed.121.263442</mixed-citation><mixed-citation xml:lang="zh">Signore A, Campagna G, Marinaccio J, et al. Analysis of Short-Term and Stable DNA Damage in Patients with Differentiated Thyroid Cancer Treated with 131I in Hypothyroidism or with Recombinant Human Thyroid-Stimulating Hormone for Remnant Ablation. Journal of Nuclear Medicine. 2022;63(10):1515–1522. doi: 10.2967/jnumed.121.263442</mixed-citation></citation-alternatives></ref><ref id="B107"><label>107.</label><citation-alternatives><mixed-citation xml:lang="en">Sohn SY, Choi JY, Jang HW, et al. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer. Thyroid. 2013;23(6):741–747. doi: 10.1089/thy.2012.0136</mixed-citation><mixed-citation xml:lang="ru">Sohn S.Y., Choi J.Y., Jang H.W., et al. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer // Thyroid. 2013. Vol. 23, N 6. P. 741–747. doi: 10.1089/thy.2012.0136</mixed-citation><mixed-citation xml:lang="zh">Sohn SY, Choi JY, Jang HW, et al. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer. Thyroid. 2013;23(6):741–747. doi: 10.1089/thy.2012.0136</mixed-citation></citation-alternatives></ref><ref id="B108"><label>108.</label><citation-alternatives><mixed-citation xml:lang="en">Lakshmanan M, Schaffer A, Robbins J, Reynolds J, Norton J. A simplified low iodine diet in I-131 scanning and therapy of thyroid cancer. Clinical Nuclear Medicine. 1988;13(12):866–868. doi: 10.1097/00003072-198812000-00003</mixed-citation><mixed-citation xml:lang="ru">Lakshmanan M., Schaffer A., Robbins J., Reynolds J., Norton J. A simplified low iodine diet in I-131 scanning and therapy of thyroid cancer // Clinical Nuclear Medicine. 1988. Vol. 13, N 12. P. 866–868. doi: 10.1097/00003072-198812000-00003</mixed-citation><mixed-citation xml:lang="zh">Lakshmanan M, Schaffer A, Robbins J, Reynolds J, Norton J. A simplified low iodine diet in I-131 scanning and therapy of thyroid cancer. Clinical Nuclear Medicine. 1988;13(12):866–868. doi: 10.1097/00003072-198812000-00003</mixed-citation></citation-alternatives></ref><ref id="B109"><label>109.</label><citation-alternatives><mixed-citation xml:lang="en">Maxon HR, Thomas SR, Boehringer A, et al. Low iodine diet in I-131 ablation of thyroid remnants. Clinical Nuclear Medicine. 1983;8(3):123–126. doi: 10.1097/00003072-198303000-00006</mixed-citation><mixed-citation xml:lang="ru">Maxon H.R., Thomas S.R., Boehringer A., et al. Low iodine diet in I-131 ablation of thyroid remnants // Clinical Nuclear Medicine. 1983. Vol. 8, N 3. P. 123–126. doi: 10.1097/00003072-198303000-00006</mixed-citation><mixed-citation xml:lang="zh">Maxon HR, Thomas SR, Boehringer A, et al. Low iodine diet in I-131 ablation of thyroid remnants. Clinical Nuclear Medicine. 1983;8(3):123–126. doi: 10.1097/00003072-198303000-00006</mixed-citation></citation-alternatives></ref><ref id="B110"><label>110.</label><citation-alternatives><mixed-citation xml:lang="en">Tala Jury HP, Castagna MG, Fioravanti C, et al. Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. Journal of Clinical Endocrinology and Metabolism. 2010;95(1):230–237. doi: 10.1210/jc.2009-1624</mixed-citation><mixed-citation xml:lang="ru">Tala Jury H.P., Castagna M.G., Fioravanti C., et al. Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients // Journal of Clinical Endocrinology and Metabolism. 2010. Vol. 95, N 1. P. 230–237. doi: 10.1210/jc.2009-1624</mixed-citation><mixed-citation xml:lang="zh">Tala Jury HP, Castagna MG, Fioravanti C, et al. Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. Journal of Clinical Endocrinology and Metabolism. 2010;95(1):230–237. doi: 10.1210/jc.2009-1624</mixed-citation></citation-alternatives></ref><ref id="B111"><label>111.</label><citation-alternatives><mixed-citation xml:lang="en">Lee M, Lee YK, Jeon TJ, et al. Low iodine diet for one week is sufficient for adequate preparation of high dose radioactive iodine ablation therapy of differentiated thyroid cancer patients in iodine-rich areas. Thyroid. 2014;24(8):1289–1296. doi: 10.1089/thy.2013.0695</mixed-citation><mixed-citation xml:lang="ru">Lee M., Lee Y.K., Jeon T.J., et al. Low iodine diet for one week is sufficient for adequate preparation of high dose radioactive iodine ablation therapy of differentiated thyroid cancer patients in iodine-rich areas // Thyroid. 2014. Vol. 24, N 8. P. 1289–1296. doi: 10.1089/thy.2013.0695</mixed-citation><mixed-citation xml:lang="zh">Lee M, Lee YK, Jeon TJ, et al. Low iodine diet for one week is sufficient for adequate preparation of high dose radioactive iodine ablation therapy of differentiated thyroid cancer patients in iodine-rich areas. Thyroid. 2014;24(8):1289–1296. doi: 10.1089/thy.2013.0695</mixed-citation></citation-alternatives></ref><ref id="B112"><label>112.</label><citation-alternatives><mixed-citation xml:lang="en">Tobey AE, Hongxiu L, Auh S, et al. Urine iodine excretion exceeding 250 ug/24h is associated with higher likelihood of progression in intermediate and high-risk thyroid cancer patients treated with radioactive iodine [abstract]. Thyroid. 2018;28 Suppl. 1:A40–A41</mixed-citation><mixed-citation xml:lang="ru">Tobey A.E., Hongxiu L., Auh S., et al. Urine iodine excretion exceeding 250 ug/24h is associated with higher likelihood of progression in intermediate and high-risk thyroid cancer patients treated with radioactive iodine [abstract] // Thyroid. 2018. Vol. 28, Suppl. 1. P. A40–A41</mixed-citation><mixed-citation xml:lang="zh">Tobey AE, Hongxiu L, Auh S, et al. Urine iodine excretion exceeding 250 ug/24h is associated with higher likelihood of progression in intermediate and high-risk thyroid cancer patients treated with radioactive iodine [abstract]. Thyroid. 2018;28 Suppl. 1:A40–A41</mixed-citation></citation-alternatives></ref><ref id="B113"><label>113.</label><citation-alternatives><mixed-citation xml:lang="en">Pluijmen MJ, Eustatia-Rutten C, Goslings BM, et al. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clinical Endocrinology. 2003;58(4):428–435. doi: 10.1046/j.1365-2265.2003.01735.x</mixed-citation><mixed-citation xml:lang="ru">Pluijmen M.J., Eustatia-Rutten C., Goslings B.M., et al. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma // Clinical Endocrinology. 2003. Vol. 58, N 4. P. 428–435. doi: 10.1046/j.1365-2265.2003.01735.x</mixed-citation><mixed-citation xml:lang="zh">Pluijmen MJ, Eustatia-Rutten C, Goslings BM, et al. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clinical Endocrinology. 2003;58(4):428–435. doi: 10.1046/j.1365-2265.2003.01735.x</mixed-citation></citation-alternatives></ref><ref id="B114"><label>114.</label><citation-alternatives><mixed-citation xml:lang="en">Morris LF, Wilder MS, Waxman AD, Braunstein GD. Reevaluation of the impact of a stringent low-iodine diet on ablation rates in radioiodine treatment of thyroid carcinoma. Thyroid. 2001;11(8):749–755. doi: 10.1089/10507250152484583</mixed-citation><mixed-citation xml:lang="ru">Morris L.F., Wilder M.S., Waxman A.D., Braunstein G.D. Reevaluation of the impact of a stringent low-iodine diet on ablation rates in radioiodine treatment of thyroid carcinoma // Thyroid. 2001. Vol. 11, N 8. P. 749–755. doi: 10.1089/10507250152484583</mixed-citation><mixed-citation xml:lang="zh">Morris LF, Wilder MS, Waxman AD, Braunstein GD. Reevaluation of the impact of a stringent low-iodine diet on ablation rates in radioiodine treatment of thyroid carcinoma. Thyroid. 2001;11(8):749–755. doi: 10.1089/10507250152484583</mixed-citation></citation-alternatives></ref><ref id="B115"><label>115.</label><citation-alternatives><mixed-citation xml:lang="en">Yoo IDKS, Kim SH, Seo YY, et al. The success rate of initial (131) i ablation in differentiated thyroid cancer: comparison between less strict and very strict low iodine diets. Nuclear Medicine and Molecular Imaging. 2012;46(1):34–40. doi: 10.1007/s13139-011-0111-y</mixed-citation><mixed-citation xml:lang="ru">Yoo I.D.K.S., Kim S.H., Seo Y.Y., et al. The success rate of initial (131) i ablation in differentiated thyroid cancer: comparison between less strict and very strict low iodine diets // Nuclear Medicine and Molecular Imaging. 2012. Vol. 46, N 1. P. 34–40. doi: 10.1007/s13139-011-0111-y</mixed-citation><mixed-citation xml:lang="zh">Yoo IDKS, Kim SH, Seo YY, et al. The success rate of initial (131) i ablation in differentiated thyroid cancer: comparison between less strict and very strict low iodine diets. Nuclear Medicine and Molecular Imaging. 2012;46(1):34–40. doi: 10.1007/s13139-011-0111-y</mixed-citation></citation-alternatives></ref><ref id="B116"><label>116.</label><citation-alternatives><mixed-citation xml:lang="en">Ito S, Iwano S, Kato K, Naganawa S. Predictive factors for the outcomes of initial I-131 low-dose ablation therapy to Japanese patients with differentiated thyroid cancer. journal article. Annals of Nuclear Medicine. 2018;32(6):418–424. doi: 10.1007/s12149-018-1261-0</mixed-citation><mixed-citation xml:lang="ru">Ito S., Iwano S., Kato K., Naganawa S. Predictive factors for the outcomes of initial I-131 low-dose ablation therapy to Japanese patients with differentiated thyroid cancer. journal article // Annals of Nuclear Medicine. 2018. Vol. 32, N 6. P. 418–424. doi: 10.1007/s12149-018-1261-0</mixed-citation><mixed-citation xml:lang="zh">Ito S, Iwano S, Kato K, Naganawa S. Predictive factors for the outcomes of initial I-131 low-dose ablation therapy to Japanese patients with differentiated thyroid cancer. journal article. Annals of Nuclear Medicine. 2018;32(6):418–424. doi: 10.1007/s12149-018-1261-0</mixed-citation></citation-alternatives></ref><ref id="B117"><label>117.</label><citation-alternatives><mixed-citation xml:lang="en">Lim CY, Kim JY, Yoon MJ, et al. Effect of a low iodine diet vs. restricted iodine diet on postsurgical preparation for radioiodine ablation therapy in thyroid carcinoma patients. Yonsei Medical Journal. 2015;56(4):1021–1027. doi: 10.3349/ymj.2015.56.4.1021</mixed-citation><mixed-citation xml:lang="ru">Lim C.Y., Kim J.Y., Yoon M.J., et al. Effect of a low iodine diet vs. restricted iodine diet on postsurgical preparation for radioiodine ablation therapy in thyroid carcinoma patients // Yonsei Medical Journal. 2015. Vol. 56, N 4. P. 1021–1027. doi: 10.3349/ymj.2015.56.4.1021</mixed-citation><mixed-citation xml:lang="zh">Lim CY, Kim JY, Yoon MJ, et al. Effect of a low iodine diet vs. restricted iodine diet on postsurgical preparation for radioiodine ablation therapy in thyroid carcinoma patients. Yonsei Medical Journal. 2015;56(4):1021–1027. doi: 10.3349/ymj.2015.56.4.1021</mixed-citation></citation-alternatives></ref><ref id="B118"><label>118.</label><citation-alternatives><mixed-citation xml:lang="en">Kim HK, Lee SY, Lee JI, et al. Daily urine iodine excretion while consuming a low-iodine diet in preparation for radioactive iodine therapy in a high iodine intake area. Clinical Endocrinology. 2011;75(6):851–856. doi: 10.1111/j.1365-2265.2011.04157.x</mixed-citation><mixed-citation xml:lang="ru">Kim H.K., Lee S.Y., Lee J.I., et al. Daily urine iodine excretion while consuming a low-iodine diet in preparation for radioactive iodine therapy in a high iodine intake area // Clinical Endocrinology. 2011. Vol. 75, N 6. P. 851–856. doi: 10.1111/j.1365-2265.2011.04157.x</mixed-citation><mixed-citation xml:lang="zh">Kim HK, Lee SY, Lee JI, et al. Daily urine iodine excretion while consuming a low-iodine diet in preparation for radioactive iodine therapy in a high iodine intake area. Clinical Endocrinology. 2011;75(6):851–856. doi: 10.1111/j.1365-2265.2011.04157.x</mixed-citation></citation-alternatives></ref><ref id="B119"><label>119.</label><citation-alternatives><mixed-citation xml:lang="en">Tomoda C, Uruno T, Takamura Y, et al. Reevaluation of stringent low iodine diet in outpatient preparation for radioiodine examination and therapy. Endocrine Journal. 2005;52(2):237–240. doi: 10.1507/endocrj.52.237</mixed-citation><mixed-citation xml:lang="ru">Tomoda C., Uruno T., Takamura Y., et al. Reevaluation of stringent low iodine diet in outpatient preparation for radioiodine examination and therapy // Endocrine Journal. 2005. Vol. 52, N 2. P. 237–240. doi: 10.1507/endocrj.52.237</mixed-citation><mixed-citation xml:lang="zh">Tomoda C, Uruno T, Takamura Y, et al. Reevaluation of stringent low iodine diet in outpatient preparation for radioiodine examination and therapy. Endocrine Journal. 2005;52(2):237–240. doi: 10.1507/endocrj.52.237</mixed-citation></citation-alternatives></ref><ref id="B120"><label>120.</label><citation-alternatives><mixed-citation xml:lang="en">Sohaimi WF, Abdul Manap M, Kasilingam L, et al. Randomised controlled trial of one-week strict low-iodine diet versus one-week non-specified low iodine diet in differentiated thyroid carcinoma. Iranian Journal of Nuclear Medicine. 2019;27(2):99–105.</mixed-citation><mixed-citation xml:lang="ru">Sohaimi W.F., Abdul Manap M., Kasilingam L., et al. Randomised controlled trial of one-week strict low-iodine diet versus one-week non-specified low iodine diet in differentiated thyroid carcinoma // Iranian Journal of Nuclear Medicine. 2019. Vol. 27, N 2. P. 99–105.</mixed-citation><mixed-citation xml:lang="zh">Sohaimi WF, Abdul Manap M, Kasilingam L, et al. Randomised controlled trial of one-week strict low-iodine diet versus one-week non-specified low iodine diet in differentiated thyroid carcinoma. Iranian Journal of Nuclear Medicine. 2019;27(2):99–105.</mixed-citation></citation-alternatives></ref><ref id="B121"><label>121.</label><citation-alternatives><mixed-citation xml:lang="en">Dekker BL, Links MH, Muller Kobold AC, et al. Low-Iodine Diet of 4 Days Is Sufficient Preparation for 131I Therapy in Differentiated Thyroid Cancer Patients. The Journal of Clinical Endocrinology &amp; Metabolism. 2022;107(2):e604–e611. doi: 10.1210/clinem/dgab691</mixed-citation><mixed-citation xml:lang="ru">Dekker B.L., Links M.H., Muller Kobold A.C., et al. Low-Iodine Diet of 4 Days Is Sufficient Preparation for 131I Therapy in Differentiated Thyroid Cancer Patients // The Journal of Clinical Endocrinology &amp; Metabolism. 2022. Vol. 107, N 2. P. e604–e611. doi: 10.1210/clinem/dgab691</mixed-citation><mixed-citation xml:lang="zh">Dekker BL, Links MH, Muller Kobold AC, et al. Low-Iodine Diet of 4 Days Is Sufficient Preparation for 131I Therapy in Differentiated Thyroid Cancer Patients. The Journal of Clinical Endocrinology &amp; Metabolism. 2022;107(2):e604–e611. doi: 10.1210/clinem/dgab691</mixed-citation></citation-alternatives></ref><ref id="B122"><label>122.</label><citation-alternatives><mixed-citation xml:lang="en">Padovani RP, Maciel RM, Kasamatsu TS, et al. Assessment of the Effect of Two Distinct Restricted Iodine Diet Durations on Urinary Iodine Levels (Collected over 24 h or as a Single-Spot Urinary Sample) and Na (+)/I (-) Symporter Expression. European Thyroid Journal. 2015;4(2):99–105. doi: 10.1159/000433426</mixed-citation><mixed-citation xml:lang="ru">Padovani R.P., Maciel R.M., Kasamatsu T.S., et al. Assessment of the Effect of Two Distinct Restricted Iodine Diet Durations on Urinary Iodine Levels (Collected over 24 h or as a Single-Spot Urinary Sample) and Na (+)/I (-) Symporter Expression // European Thyroid Journal. 2015. Vol. 4, N 2. P. 99–105. doi: 10.1159/000433426</mixed-citation><mixed-citation xml:lang="zh">Padovani RP, Maciel RM, Kasamatsu TS, et al. Assessment of the Effect of Two Distinct Restricted Iodine Diet Durations on Urinary Iodine Levels (Collected over 24 h or as a Single-Spot Urinary Sample) and Na (+)/I (-) Symporter Expression. European Thyroid Journal. 2015;4(2):99–105. doi: 10.1159/000433426</mixed-citation></citation-alternatives></ref><ref id="B123"><label>123.</label><citation-alternatives><mixed-citation xml:lang="en">Park JT, Hennessey JV. Two-week low iodine diet is necessary for adequate outpatient preparation for radioiodine rhTSH scanning in patients taking levothyroxine. Thyroid. 2004;14(1):57–63. doi: 10.1089/105072504322783858</mixed-citation><mixed-citation xml:lang="ru">Park J.T., Hennessey J.V. Two-week low iodine diet is necessary for adequate outpatient preparation for radioiodine rhTSH scanning in patients taking levothyroxine // Thyroid. 2004. Vol. 14, N 1. P. 57–63. doi: 10.1089/105072504322783858</mixed-citation><mixed-citation xml:lang="zh">Park JT, Hennessey JV. Two-week low iodine diet is necessary for adequate outpatient preparation for radioiodine rhTSH scanning in patients taking levothyroxine. Thyroid. 2004;14(1):57–63. doi: 10.1089/105072504322783858</mixed-citation></citation-alternatives></ref><ref id="B124"><label>124.</label><citation-alternatives><mixed-citation xml:lang="en">Dekker BL, Touw DJ, van der Horst-Schrivers ANA, et al. Use of Salivary Iodine Concentrations to Estimate the Iodine Status of Adults in Clinical Practice. The Journal of Nutrition. 2021;151(12):3671–3677. doi: 10.1093/jn/nxab303</mixed-citation><mixed-citation xml:lang="ru">Dekker B.L., Touw D.J., van der Horst-Schrivers A.N.A., et al. Use of Salivary Iodine Concentrations to Estimate the Iodine Status of Adults in Clinical Practice // The Journal of Nutrition. 2021. Vol. 151, N 12. P. 3671–3677. doi: 10.1093/jn/nxab303</mixed-citation><mixed-citation xml:lang="zh">Dekker BL, Touw DJ, van der Horst-Schrivers ANA, et al. Use of Salivary Iodine Concentrations to Estimate the Iodine Status of Adults in Clinical Practice. The Journal of Nutrition. 2021;151(12):3671–3677. doi: 10.1093/jn/nxab303</mixed-citation></citation-alternatives></ref></ref-list></back></article>
